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ABSTRACT

Polypharmacy is a healthcare problem of epidemic proportions in the United States. It is
frequently associated with negative health outcomes in the lives of both elderly and chronically
ill persons at excessive costs to the United States healthcare system. Appropriate medication
management incorporating evidence-based guidelines is essential to addressing polypharmacy.
Prescribing clinicians in all disciplines have expressed a lack of confidence and perceived gaps
in knowledge to address polypharmacy through deprescribing. This scholarly project aimed to
determine if a polypharmacy protocol intervention, based on the most current evidence-based
guidelines in prescribing and deprescribing, would improve clinician confidence in the decision
making to reduce polypharmacy and increase ability to recognize potentially inappropriate
medications and potentially inappropriate prescribing omissions. The scholarly project utilized a
quasi-experimental study design with pre-intervention and post-intervention data collection using
the Clinician Polypharmacy Management Survey. Evaluation of the data demonstrated a
clinically significant increase in clinician confidence and ability in the recognition of
polypharmacy and capability to prescribe and deprescribe following the implementation of the
protocol. Although not as strong statistically, all ten areas of confidence measured, demonstrated
improvement. The results of the scholarly project agreed with the literature that implementation
of evidence-based guidelines for prescribing and deprescribing increases clinician confidence in
addressing polypharmacy.
Keywords: Polypharmacy, deprescribing, evidence-based guidelines, confidence,
potentially inappropriate medications, clinician

POLYPHARMACY INTERVENTION

4

Table of Contents
Abstract ........................................................................................................................................... 3
List of Tables .................................................................................................................................. 6
List of Abbreviations ...................................................................................................................... 7
Introduction: Polypharmacy............................................................................................................ 8
Background............................................................................................................................................... 8
Problem Statement.................................................................................................................................. 12
Purpose of the Project ............................................................................................................................. 13
Clinical Question .................................................................................................................................... 13

Literature Review.......................................................................................................................... 13
Search Strategy ....................................................................................................................................... 13
Critical Appraisal .................................................................................................................................... 14
Synthesis of Evidence............................................................................................................................. 26
Conceptual Framework........................................................................................................................... 29
Summary................................................................................................................................................. 31

Methodology ................................................................................................................................. 32
Design ..................................................................................................................................................... 32
Measurable Outcomes ............................................................................................................................ 32
Setting ..................................................................................................................................................... 33
Population ............................................................................................................................................... 33
Ethical Considerations ............................................................................................................................ 34
Data Collection and Survey Tool. .......................................................................................................... 35
Intervention............................................................................................................................................. 35
Data Analysis.......................................................................................................................................... 37

Results ........................................................................................................................................... 38
Descriptive Statistics .............................................................................................................................. 39
Measurable Outcomes ............................................................................................................................ 41

Discussion ..................................................................................................................................... 44
Implication for Practice .......................................................................................................................... 44

POLYPHARMACY INTERVENTION

5

Sustainability .......................................................................................................................................... 47
Dissemination Plan ................................................................................................................................. 48

References ..................................................................................................................................... 50
Appendix A ................................................................................................................................... 55
Appendix B ................................................................................................................................... 56
Appendix C ................................................................................................................................... 76
Appendix D ................................................................................................................................... 77
Appendix E ................................................................................................................................... 78
Appendix F.................................................................................................................................... 79
Appendix G ................................................................................................................................... 81
Appendix H ................................................................................................................................... 83

POLYPHARMACY INTERVENTION

6
List of Tables

Table 1. Scholarly Project Timeline ............................................................................................. 36
Table 2. Polypharmacy Intervention Participation by Pre-survey and Post-survey .................... 39
Table 3. General Characteristics of Project Participants ............................................................. 39
Table 4. General Perception of Polypharmacy Prevalence and Use of Deprescribing Tool ....... 40
Table 5. Paired Samples Statistics Analysis Organized by CPMS Question .............................. 41
Table 6. Paired Samples Correlations by CPMS Question .......................................................... 42
Table 7. Paired Differences by CPMS Question ......................................................................... 44

POLYPHARMACY INTERVENTION

7

List of Abbreviations
Clinician Polypharmacy Management Survey (CPMS)
Collaborative Institutional Training Initiative (CITI)
General practitioner (GP)
Hillsdale Community Hospital (HCH)
Independent nurse providers (INPs)
Institutional Review Board (IRB)
Nonsteroidal anti-inflammatory drugs (NSAIDs)
Over-the-counter (OTC)
Potentially inappropriate medications (PIMs)
Potentially inappropriate prescribing omissions (PPOs)
Random controlled trial (RCT)
Screening Tool of Older Persons’ Potentially Inappropriate Prescriptions/Screening Tool to Alert
Doctors to Right Treatment (STOPP/START)
United States (US)

POLYPHARMACY INTERVENTION

8

Introduction: Polypharmacy
Polypharmacy is defined as the regular use of multiple medications, either prescribed, overthe-counter (OTC), or a combination. The incidence of polypharmacy most often occurs in
persons receiving treatment for one or more chronic disease (Masnoon, Shakib, Kalisch-Ellett,
and Caughey, 2017). Because of the correlation between polypharmacy and chronic diseases,
older adults, by a significant percentage, have the highest prevalence of polypharmacy compared
to other age groups. A number of concerning outcomes for elderly persons have been associated
with polypharmacy, even after adjusting for chronic conditions. Research has shown these
negative outcomes to include falls, adverse drug reactions, morbidity, increased length of
hospital stays, and frequent readmissions to the hospital (Masnoon et al., 2017). Appropriate
medication management is essential to decreasing polypharmacy, beginning with the education
of all prescribing healthcare providers and continuing with up-to-date evidence-based guidelines
usage by prescribing clinicians in the practice setting (Djerbib, 2018; Kostas et al., 2014; Martin,
Tamblyn, Benedetti, Ahmed, and Tannenbaum, 2018). The general discomfort with reducing
polypharmacy through deprescribing, by healthcare providers at all levels of experience,
validates the need for evidence-based methods to address the situation (Djerbib, 2018; Farrell et
al., 2018; Mecca et al., 2019). The incorporation of prescribing and deprescribing solutions into
practice is crucial for proper medication management by clinicians.
Background
Although there was inconsistency in the literature on the characterization of polypharmacy,
research by Masnoon, et al. (2017), determined the most commonly used definition for
polypharmacy as regular use of five or more medications. The definition of older adults or
elderly persons also varied in the literature. While the age of 65 or older was the most common,
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it should be noted the youngest age included in the research is 50. For the purpose of the
scholarly project, older adults/elderly was defined as 65 years of age or older.
Related to the high prevalence of chronic disease in the elderly, polypharmacy has been a
rapidly increasing problem the last several years. In the United States (US), the prevalence of
co-morbidities of two or more chronic diseases was 61% in the elderly population (Quinn &
Shah, 2017). This frequency of chronic disease and the associated medical treatment resulted in
30% of elderly persons in the US with medication regimes reflecting polypharmacy (Quinn &
Shah, 2017). The US is not alone in the high rate of polypharmacy, as similar incidence has
been reported in many European countries, Australia, Japan, China, Brazil, Canada, and India.
The problem of polypharmacy has been seen in primary care, in-home healthcare settings, adult
long-term care facilities, and acute care hospitals.
An equally concerning situation and related cause for polypharmacy, has been the number
of inappropriate drugs prescribed for the elderly, known as potentially inappropriate medications
(PIMs) and potentially inappropriate prescribing omissions (PPOs). The occurrence of PIMs has
been estimated to be as high as 50% in the elderly population (Kua, Mak, & Huey Lee, 2019).
According to Kimura et al. (2016), PIMs are prescribed medications that involve an incorrect
dose, frequency, or mode of administration; the duration of treatment is incorrect; high risk of
clinically significant drug-drug or drug-disease interactions; or without a clear evidence-based
clinical indication. PPOs are medications that are clinically indicated for the treatment of a
certain condition or disease, or used to prevent disease in persons at risk. The incidence of
polypharmacy increases the risk for both PIMs and PPOs in the elderly population. The elderly
in the US were found to use 33% of all prescription medications and account for 40% of the
OTC drugs, supplements, and herbals. The percent of adults 65 or older was estimated to be
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15% of the US’ population in 2014, with an estimated growth to 21% by 2030 (Mather,
Jacobsen, & Pollard, 2015). Related to these projections, healthcare concerns for polypharmacy,
PIMs, and PPOs will continue to be a growing problem in the US.
According to Quinn and Shah (2017) the prevalence of polypharmacy related drug
reactions have been responsible for the acute care hospitalization of 4 of every1000 people each
year, was among the ten most common causes of death, and was estimated to cost the healthcare
system in the US upwards of $180 billion dollars annually. For the elderly population, the
burden of adverse drug effects and interactions were highest with 10-15% of all hospital
admissions in this age group related to an adverse drug effect (Löffler, et al., 2014). In addition
to increased hospitalization, it’s estimated 23% of nursing home admissions in the US were
related to problems the elderly patient experience because of polypharmacy (Pasina et al., 2014).
The data suggests polypharmacy increased the risk of falls, frailty, physical and cognitive
dysfunction, which has lead to loss of autonomy and decreased quality of life for the elderly
population (Muth et al., 2018). The far-reaching effects of polypharmacy with the immense
negative impact on the lives of elderly persons and the exorbitant costs to the healthcare system
is an issue that needs to be addressed at all levels of patient care.
The need for enhanced awareness to address polypharmacy and medical management
within primary care in the US is recognized in the research, but implementation of evidencebased solutions has been limited and inconsistent (Campins et al., 2017; Djerbib, 2018; Mecca et
al., 2019). Clinicians in multiple disciplines, including physicians, nurse practitioners, and
physician assistants, have expressed discomfort with their ability to address polypharmacy
through deprescribing. There are perceived gaps in their training, knowledge, and resources to
effectively prioritize care when patients have multiple comorbidities coupled with polypharmacy
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(Djerbib, 2018; Farrell et al., 2018; Mecca et al., 2019). Numerous reasons for clinicians’ lack of
confidence in addressing polypharmacy were identified, including: concerns for withdrawal,
ability to monitor, stopping or changing a medications prescribed by another provider, lack of
clarity related to tapering, failure in disease management, and other adverse side effects (Farrell
et al., 2018).
Polypharmacy can be appropriate and justified when treating patients with multiple
comorbidities. The challenge for the prescriber is achieving a balance between minimizing the
risks and adverse effects of polypharmacy, while maintaining optimal control of chronic disease
symptoms and progression. The situation is further complicated when patient or families are
resistant to changes or there is poor adherence to current medication regimen.
An evidence-based reduction in the number of long-term medications has shown to
decrease acute hospital length of stays and admissions, improve mortality, and reduce the
healthcare costs to individuals and the healthcare system (Löffler, et al., 2014). Several criteria
have been successfully used for reducing the burden of polypharmacy and detecting PIMs and
PPOs. The most common methods included the Beers Criteria, Improved Prescribing in the
Elderly Tool, and the Screening Tool of Older Persons’ Potentially Inappropriate
Prescriptions/Screening Tool to Alert Doctors to Right Treatment (STOPP/START) criteria
(Campins et al., 2017). Other research has confirmed the simplification of medication regimens
improved adherence and resulted in higher levels of patient satisfaction (Löffler, et al., 2014).
Implementing an evidence-base intervention aimed to improve competency of primary care
providers in medication management and polypharmacy has demonstrated success in the
research (Campins et al., 2017; Djerbib, 2018; Farrell et al., 2018; Kostas et al., 2014). Studies
by Cossette et al. (2016) and Kostas et al. (2014) revealed deprescribing tools that improved
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clinical judgment and guided decision-making, enhanced the learning experiences. Other
preferred methods included concise presentations that emphasized the relevance of a focused
educational topic, such as deprescribing, and applying the specific information to patient care
(Cossette et al., 2016). Proper training and resources increased prescribing clinicians’
confidence for developing and implementing changes to patient’s medication regimen addressing
polypharmacy, PIMs, and PPOs. An intervention to improve deprescribing and medication
management in the primary care setting will provide clinicians with an evidence-based
methodology and medication analysis tool that will increase competence in addressing
polypharmacy. A short learning session providing education on the deprescribing tool must be
focused, with clear information on usage and implementation in the practice setting. It is
important the intervention is user-friendly, efficient, and effective at addressing polypharmacy
through the reduction of PIMs, evaluation of PPOs, and takes into consideration patient
preferences.
Problem Statement
Polypharmacy affects 30% of elderly persons in the US. The burden of polypharmacy on
the elderly population in the US is reflected in increased hospitalizations and nursing home
admissions, decreased quality of life related to falls, cognitive and physical impairment, and
increased mortality. The additional cost to the US healthcare system for acute care hospital
admissions alone was estimated at $180 billion dollars in 2014. With the percentage of adults 65
or older expected to increase 50% by the year 2030, the costs of polypharmacy to individuals and
the society is a healthcare crisis in the US. Primary care providers of all disciplines are in need
of effective, easy to implement methods and tools to address polypharmacy management and
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deprescribing. To successfully address polypharmacy and reverse this worsening healthcare
crisis in the US, the use of evidence-based protocols in primary care settings are crucial.
Purpose of the Project
The purpose of the scholarly project was to implement and evaluate the effects an
evidence-based pocket-sized deprescribing tool had on primary care providers’ awareness and
confidence in addressing polypharmacy, PIMs, and PPOs during outpatient visits. The
significance of the project was the clinician’s increased understanding and ability to identify and
address polypharmacy during patient primary care visits. The primary outcome was the affect a
tool developed from evidence-based guidelines had on prescriber confidence in the deprescribing
decision making process. The secondary outcomes were a self-evaluation of skills in
recognizing PIMs and PPOs, and increased confidence to deprescribe when specific, common
barriers were encountered in the presence of polypharmacy.
Clinical Question
The clinical question was “Would primary care providers in an outpatient setting (P) with
the utilization of an evidence-based deprescribing protocol to reduce polypharmacy (I),
experience an increase in perceived awareness and confidence to initiate medication changes (O)
compared to standard practice before the introduction of the protocol (C)?”
Literature Review
Search Strategy
The search for literature began with the Jerry Falwell Library “Search Anything” box on
the main page, delimited by the option of “Articles”. Although separate searches were also
performed using multiple databases (CINAHL Plus with Full, National Guideline Clearinghouse,
Cochran Database of Systematic Reviews, ProQuest Nursing and Allied Health Database,
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EBSCO, and PubMed), the results of the “Search Anything” function provided the best
comprehensive search for the topic. The general delimiters were English language, published in
the last 5 years, journal articles only, and scholarly and peer-reviewed articles. The search string
terms of polypharmacy, elderly, research, clinical trial, intervention, PIMs, STOPP, education,
learning preference, primary care, nurse practitioner, US, and deprescribing were used in various
combinations resulting in 287 articles. After reviewing the first 100 articles, with some chosen
for the literature review and proposal, further refinement to the list was made by limiting articles
to those published in the past 3 years with a resulting 127 journal articles. Next, pilot studies,
study protocols, poorly executed or reported studies, and studies that were not pertinent to the
project were eliminated. Because the project was based in the US with a Western cultural view
of healthcare, the studies were limited to European countries, Australia, the US, Canada, and
Japan. Nineteen articles were chosen for the literature review.
Critical Appraisal
Review of the studies found seven articles with a 1 or 2 level of evidence using the Melnyk
Framework, which were selected for inclusion (Melnyk & Fineout-Overholt, 2015). An
additional nine studies with a Melnyk level of evidence of 3 or 4, including a systemic review of
cohort/case-control studies, were chosen for the strength of the studies as well as the contribution
to the evidence and knowledge of the scholarly project subject (Melnyk & Fineout-Overholt,
2015). Finally, three more research studies with a level of evidence of 5 or 6 according to the
Melnyk Framework (Melnyk & Fineout-Overholt, 2015) were chosen for their contribution to
better understanding the importance of the patient in deprescribing and an analysis of the
dynamics influencing the decision making process of primary care providers.
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Reduction of polypharmacy, PIMs, and PPOs.
A systemic review and meta-analysis by Kua et al. (2019) evaluated research studies
related to polypharmacy and deprescribing, performed among elderly residents in nursing homes.
A total of 41 randomized clinical studies were appraised for the research study, all matching the
criteria of execution in a country with a Western culture. Overall, deprescribing interventions
reduced the number of PIMs by 59% (Kua et al., 2019). Limitations in the Kua et al. (2019)
study included: dissimilarities in reporting measures for the same patient outcomes, variation in
outcomes measured among the studies, and some studies had a short study period. This study
provided strong evidence for deprescribing as an effective method to reduce PIMs. Also, while
there are a variety of methods used to accomplish deprescribing, a medication review
intervention was the most successful in improving patient outcomes.
In a random controlled trial (RCT) study by Campins et al. (2017), the STOPP/START
criteria was used effectively to reduce the cost and burden of polypharmacy through
deprescribing medications of recruited community dwelling older adults. Evaluation of the
intervention group revealed 26.5% of the prescription medications as PIMs, and a total 21.5% of
the prescription medications were either discontinued, substituted, or dose adjusted (Campins et
al., 2017). Also, 95.6% of the intervention group had at least one recommended change to
medications (Campins et al., 2017). Continued assessments at three, six, and twelve months
showed the number of prescriptions per intervention patient was significantly lower compared to
the control group (Campins et al., 2017). Limitations in the Campins et al. (2017) research
included potential contagion of groups, with physicians having patients in each arm of the study.
The study by Clyne et al. (2016) was a mixed method study involving an RCT and a
qualitative semi-structured interview. A three-phase intervention was conducted in general
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practitioner (GP) practices to reduce PIMs for older adults, and evaluated the execution and
effectiveness of each of the three phases (Clyne et al., 2016). Results found just over 70% of the
practices completed the medication review with the patient present (Clyne et al., 2016). Even so,
the research demonstrated the effectiveness of the interventions to reduce PIMs in the elderly.
Limitation involved the inability to capture a meaningful volume of qualitative data.
Next, the RCT study by Martin et al. (2018) was a pharmacist-led intervention, with
recommendations for deprescribing using the Beers Criteria sent to the physician and educational
deprescribing brochure to the patient. The study involved community pharmacies and recruited
elderly patients each prescribed one or more Beers Criteria medications. Evaluation at six
months revealed 43% of the intervention group no longer received prescriptions for the PIMs,
compared to 12% of the control group. Two noted limitations, included the confounding change
in guidelines calling for the discontinuation of glyburide, and the small recruitment of patients
using nonsteroidal anti-inflammatory drugs (NSAIDs) or first generation antihistamines. The
association and reliability of using the Beers Criteria for deprescribing with positive patient
outcomes, is strengthened.
By trialing a computer decision support system in general practices, the RCT study by
Muth et al. (2018), investigated if the intervention would show improvement in number of PIMs
utilized by elderly with multiple co-morbidities. While results of this study showed no
significant changes in patient prescriptions, quality of life, or functional status, it should be noted
both the control and intervention groups had few medications identified as PIMs, and high
functional status and quality of life indicators at the beginning of the study. Limitations included
the Hawthorne effect with intense data collection at every visit, the lower age limit of 60 for
participants, and an arbitrary definition of polypharmacy. The study still provided important
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outcomes to consider in the overall scope of the proposed project, especially involving the
importance of limiting the prescribing of PIMs.
The research study by Potter, Flicker, Page, and Etherton-Beer (2016) was a RCT aimed to
reduce polypharmacy and PIMs usage by elderly in residential aged care facilities through
medication reviews by a pharmacist and GP. In the intervention group, 348 medications were
identified for deprescribing, with a total of 207 (59%) medications successfully discontinued
(Potter et al., 2016). The primary limitations of the study were the small number of participants
and an open design, which can lead to treatment bias. Successfully deprescribing without
adverse health outcomes evidenced the importance of this study.
In the RCT study by Schäfer et al. (2018), the intervention involved three 30-minute
consolations by the GP, expected to demonstrate a reduction in polypharmacy, without a
negative affect on quality of life. During the 12-month study, there was no statistically
significant difference, between the intervention and control groups related to change in number
of medications used or quality of life indicators (Schäfer et al., 2018). The intervention group
was twice as likely to receive a new prescription for an analgesic compared to the control group.
Major study limitations were unobserved consults, study volunteers may have been more
cooperative, and higher satisfaction with their GP compared to the population. In the instance of
this study, a high intensity intervention demonstrated a neutral impact on the degree of
polypharmacy.
Research by Van der Linden et al. (2017), was a quasi-experimental design study that
assessed the effect of a pharmacist medications review with the application of the STOPP criteria
to elderly patients’ home medications. The patients were admitted to an acute geriatric ward in a
university hospital. The results of the study demonstrated the intervention group had more
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medications discontinued at discharge, including a higher number of PIMs, compared to the
control group. Re-evaluation of both groups, 3 months after discharge, revealed patients in the
intervention group continued to have less PIMs prescribed without adverse health events.
Limitations of the study were lack of randomization and a follow-up period of only three months.
The safe reduction of polypharmacy and PIMs in elderly patients with the use of the STOPP
protocol demonstrated a positive effect on the quality of life.
A cohort study completed by Kimura et al. (2017), evaluated the efficacy of a medication
review by hospital pharmacists using the STOPP criteria to deprescribe PIMs in elderly patients.
Of the participants in the study, 346 were identified as having one or more PIMs. The
intervention identified 310 PIMs to be discontinued, resulting in a total of 292 PIMs either
discontinued or modified (Kimura et al. (2017). Limitations of the study included
generalizability, initial reasons for prescribing of PIMs were not considered for deprescribing,
and no evaluation of patient outcomes with discontinuation of PIMs. The research demonstrated
prescribing of PIMs to be a significant problem in the elderly and can be effectively addressed
using tools that are currently available.
The next study was a correlational design cohort study by Komagamine and Hagane (2017)
that evaluated the effectiveness of an internal medicine physician medication assessment, for
patients admitted with hip fractures. The intervention considered evidence-based use for the
medication, valid indication related to age and disability level, harm versus benefits, and
availability of a superior medication or non-pharmacological treatment (Komagamine & Hagane,
2017). The total prescribed PIMs was statistically lower at discharge in the intervention group.
No significant differences were observed in clinical outcomes at the six-month follow-up
comparing the intervention and control group. Limitations were related to the study’s
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retrospective observational design, no follow-up for adverse reactions, and long-term outcomes.
Including only a special subset of patients may dilute the real effects of the interventions. Even
with the limitations, the study showed deprescribing an effective approach to reducing PIMs.
The quasi-experimental cohort study by Urfer, Elzi, Dell-Kuster, and Bassetti (2016),
assessed the safety and efficacy of a prescriber checklist using the STOPP/START criteria for
reducing polypharmacy and PIMs and addressing PPOs. The study involved elderly patients
hospitalized in the internal medicine wards. At admission and evaluation of both control and
intervention groups, 59% had medication regimens reflecting polypharmacy, 37% had one, or
more PIMs and 25% had one or more PPOs (Urfer et al., 2016). The intervention arm of the
study demonstrated a 22% reduction in PIMs at discharge. In addition, there was an overall
decrease in the number of total prescription medications at discharge, but less than the 20%
theorized, and the reduction of PPOs at discharge was lower than expected (Urfer et al., 2016).
The primary limitations experienced by the study are reduced strength of evidence compared to
an RCT, and decreased generalizability related to a single site study. The strength of this study
is an easy to use intervention producing a significant reduction in PIMs at discharge.
Association of polypharmacy and adverse outcomes.
Fried et al. (2014) conducted a systematic review of fifty observational studies, with four
case-control studies and the rest identified as cross-sectional or longitudinal cohort studies. The
purpose of the research was to summarize the health outcomes associated with polypharmacy in
elderly community-dwelling persons. Results revealed the majority of the studies receiving a
good rating, in terms of adjustment for comorbidities, demonstrated a significant relationship
between polypharmacy and adverse outcomes. The adverse outcomes patients experienced were
comprised of increased fall risk factors, falls, negative fall outcomes, patient decreased function
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and cognition, and adverse drug events resulting in drug interactions, hospitalizations, and
mortality (Fried et al., 2014). The strongest relationship was falls associated with polypharmacy
in the better-rated studies. A few inconsistent results occurred with some studies rated as good
that did not reveal a relationship between polypharmacy and adverse effects. Also, some studies
rated as fair or poor, in terms of adjustments for comorbidities, did indicate an association
between adverse effects and polypharmacy. Limitations identified were heterogeneity in the
study populations and differing definitions of polypharmacy that made direct comparisons
between studies very challenging (Fried et al., 2014). Relevant studies were likely missed
considering many were found through reference lists, rather than database searches. A widevariety in types of medications included or excluded was identified among the studies. Overall,
a definitive association could not be made between polypharmacy and the adverse events listed
above, but there were good associations and when considered along with other research, this
study does support the relationship.
Patient secondary outcomes.
In the systemic review by Kua et al. (2019), the results showed that even with variety in
reporting, deprescribing had significant impact on patient outcomes. Further analysis of the data
comparing the different type of deprescribing interventions, a medication review-directed
intervention was shown to reduce the number of residents experiencing falls by 24% and allcause mortality reduced by 26% (Kua et al., 2019). The Martin et al., (2018) RCT was
significant for no adverse events requiring hospitalization within the intervention group at the
six-month evaluation after deprescribing. In the Potter et al. (2016) study the intervention group
showed improved mortality at the 12-month evaluation. Other secondary outcomes studied:
fractures, falls, hospital admissions, sleep, bowel function, physical function, cognition, quality
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of life; had no significant differences between the intervention and control groups, possibly
influenced by the number of study participants (Potter et al., 2016). The Schäfer et al. (2018)
RCT displayed the number of hospital days was reduced in the intervention group but did not
effect the degree of polypharmacy in the intervention group. At three months post-discharge in
the Van der Linden et al. (2017) study, the safe reduction of polypharmacy and PIMs in elderly
patients in the intervention arm showed a positive effect on quality of life, including a downward
trend in emergency department visits and hospital readmission, compared to the control group.
Not all studies had the sample size necessary to properly assess secondary outcomes. In
the RCT by Campins et al. (2017), the sample size was small with limited statistical power for
the evaluation of secondary outcomes for emergency department visits, hospitalizations, and
deaths. Another study producing no significant results was the Muth et al. (2018) RCT, where
the patient population in both arms had a small occurrence of polypharmacy and PIMs.
Furthermore, studies by Clyne et al. (2016), Kimura et al. (2017), Komagamine and Hagane
(2017), and Urfer et al. (2016) did not perform measurements on secondary outcomes.
Patient participation.
Many studies identified the importance of patient participation in the deprescribing process.
The study by Clyne et al. (2016) demonstrated changes to current medication regimens were
more successful when the patient was present, reinforcing the importance of patient participation.
Research by the Martin et al. (2018) also strengthened the concept when patient education was
proven to be critical for deprescribing PIMs. The study by Komagamine and Hagane (2017),
employed a protocol where the physician involved the patient or caregiver in the decision
making process for deprescribing.
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The next two research studies although qualitative studies, add significant knowledge to the
subject of polypharmacy and patient point of view. The study by Pasina et al. (2014) aimed to
describe adherence to medication regimen in elderly patients identified with polypharmacy after
hospital discharge. Participants were contacted for telephone interviews at 2-4 weeks and three
months after discharge. Results of the first follow-up call reflected patient non-adherence to
medication regimens at 55.1% and at the second follow-up call, the non-adherence rate rose to
69.9% (Pasina et al., 2014). Furthermore, only 28.1% of patients reported understanding the
reasons for their medications during the first call, and decreased to 25.3% during the second call
at three month (Pasina et al., 2014). Limitations include small sample size, overestimation of
adherence from self-reporting, and no information collected for clinical outcomes associated
with non-adherence. The information revealed by the study provided a strong rational to reduce
polypharmacy and simplify elderly patients’ medication regimens. Also, the need for patient
friendly education, better communication related to medication importance, and the need for
improved understanding of medical diagnoses associated with the drug.
The qualitative study by Snell, Langran, and Donyai (2017) investigated elderly patients’
perspective utilizing a questionnaire, for a pharmacist initiated, medication review addressing
polypharmacy at the GP clinics. The medication reviews prompted a total of 901 medicationsrelated changes (Snell et al., 2017). The review and educational intervention was found helpful
by 83% of respondents, with 80% expressing a better understanding of their medications, and
94% stating medication-related concerns were addressed during the intervention (Snell et al.,
2017). Limitations were only 51% of the eligible patients attended a medication review with
only 40% of attendees completing a feedback questionnaire. Also, the longevity of the
intervention was not evaluated. Patients overwhelmingly perceived the medication reviews
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positively. The study reinforced the concept that patients’ understanding their medication is an
important and crucial step in deprescribing and addressing polypharmacy among the elderly.
Clinician competency and evidence-based deprescribing protocols.
As exampled in the Martin et al. (2018) RCT, the importance of evidence-based
deprescribing protocols for the prescriber was a consistent theme in the literature. Primary care
prescribers in the US have a vital role in the reduction of polypharmacy and PIMs, as well as the
appropriate prescribing of PPOs. Medication management and pharmacology are vital
competences for medical trainees of multiple disciplines. Learning to manage polypharmacy is a
growing phenomenon in healthcare, which needs to first be addressed during the education of
future prescribers (Kostas et al., 2014). Early and regular exposure to the topic of polypharmacy
and methods utilized to address the issue, are important to increasing confidence and competency
of all clinicians during their journey to independent practitioner and beyond.
A qualitative systemic review by Djerbib (2018) evaluated research studies related to the
dynamics that influence the prescribing decision making process by primary care independent
nurse providers (INPs) in the United Kingdom. A total of 10 qualitative research studies were
appraised for the systemic review, all meeting the inclusion criteria: INPs, primary care practice
setting, prescribing decision-making, peer-reviewed, and studies performed in the United
Kingdom. The INPs identified three major themes that influence prescribing decisions:
perception of competence, perception of risk, and impact on the patient. Related to the
perception of competence, there was a preference for use of evidence-based guidelines and
formularies to facilitate decision-making. The INPs identified patients with complex problems
and polypharmacy to increase the risks of prescribing. Impact on the patient was the third
concern expressed by the INPs, involving adherence, clinical need for the prescription, and
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patient costs. In comparison to similar research on GPs, it was found that GPs also identified the
same three major themes as influencing the prescribing process. The research provides
important insight to clinicians’ concerns related to competence, concerns for polypharmacy, and
patient participation when prescribing, as well as a preference for the use of evidence-based
guidelines. The major limitation of the study was a single reviewer of the systematic review
with a potential for bias and decreased transparency.
In a quasi-experimental design study performed by Cossette et al. (2016), the aim was to
evaluate the effects of a strategy using multiple interventions on the prescribing behaviors of
physicians in the acute hospital setting. The outcome of the research was an absolute decrease in
PIMs usage of 3.5%, which showed significant decrease in physician prescribing of new PIMs
(Cossette et al., 2016). Interventions in the multi-strategy protocol included evidence-based
educational material on PIMs targeted for non-introduction during hospitalization and
educational presentation targeted to specific clinician groups. Barriers identified to
deprescribing were pre-hospital use of PIMs and lack of information for alternative nonpharmacological or preferred/safer pharmacological options.
The research study by Farrell et al. (2018) investigated whether the implementation of
evidence-based deprescribing guidelines would increase the confidence of clinicians to actively
reduce and stop medications that identified as PIMs. The quasi-experimental design participants
were physicians, nurse practitioners, and pharmacists both in long-term care facilities and family
health practices. Over the eighteen month study, the final analysis showed a significant, overall
increase in clinicians’ confidence in deprescribing across multiple drug classes, when the
guidelines were routinely utilized (Farrell et al., 2018). Setting did affect outcomes with the
clinicians in the long-term care facilities having the highest increases in confidence and action
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related to deprescribing. The most notable limitations in the Farrell et al. (2018) research, were
the lack of psychometric testing of the instrument and low number of survey respondents.
In the next study, the Beers Criteria was the basis for the implementation of a workshop
with the goal to improve medical trainees confidence and ability to perform accurate medication
reviews (Kostas et al., 2014). The participants were internal medicine residents, physician
assistant students, and geriatric fellows. Participants first completed a needs assessment, which
identified medications management and polypharmacy, as one of the five most important
learning topics (Kostas et al., 2014). Three months after attending the workshop 71% of
participants reported making changes to patient medication regimens as a result of the
information learned in the workshop (Kostas et al., 2014). The major limitations were a pre-post
survey quasi-experimental design, without a control group, conducted at a single site, and low
participation rate in the follow-up survey (Kostas et al., 2014). Even with these limitations, the
improvement in the participants ability to identify appropriate medications for deprescribing,
followed by taking action and making changes in the clinical setting, shows the strength of
evidence-based deprescribing protocols in addressing polypharmacy.
Research by Mecca et al. (2019) assessed the impact an educational intervention had on the
knowledge and perceptions of internal medicine and nurse practitioner residents related to
polypharmacy, complex medication management, and deprescribing PIMs. The study was
conducted at a veterans’ primary care clinic with an intervention and control group in a quasiexperimental design study. The intervention centered on a complete medication review with
analysis using evidence-based tools, guidelines, and calculators to develop a deprescribing
strategy. Six months after the original intervention, both groups were given a post-test to
evaluate polypharmacy knowledge. The intervention group’s test scores averaged 14% higher
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when compared to their pre-educational program test versus the control group’s 1.3% average
post-test increase. In addition, the intervention group perceived an improvement in knowledge
and skills, and showed positive changes in the clinical setting demonstrated by an average of two
discontinued medications for each veteran. Study limitations were the small number of residents
and no long-term evaluation of discontinued medications. The research validates the consistent
theme of clinician use of evidence-based deprescribing methods as an effective intervention to
reduce polypharmacy, while building confidence and ability for improved care.
The articles selected for the literature review provided a strong basis for reducing
polypharmacy through appropriate prescribing of PIMs and PPOs. The research reviewed
included similar interventions implemented in both inpatient and outpatient settings, with
positive outcomes independent of setting. Involvement of all prescribing medical disciplines is
vital to managing polypharmacy. The studies demonstrated the initiation of evidence-based
interventions with the specific aim to manage polypharmacy, have successfully raised clinicians’
awareness, competence, and confidence in implementing protocols for deprescribing. Finally,
encouraging patient involvement in the deprescribing process is an important component that
needs to be considered by the prescriber for the successful of reduction of polypharmacy.
Synthesis of Evidence
The use of deprescribing is endorsed in the literature review as the key to addressing the
problem of polypharmacy in elderly persons. Deprescribing is described as the reduction,
substitution or discontinuation of unnecessary or inappropriate medications (Kua et al., 2019).
This theme was validated in other research. Further delving into methods of deprescribing
focused on medications identified as PIMs. In addition, several of the research articles gave

POLYPHARMACY INTERVENTION

27

equal importance to evaluating and correcting medications identified as PPOs, based on patient
diagnoses.
It was found deprescribing commonly followed a specific framework among the studies,
starting with a comprehensive medication review and medical history including prescription and
OTC drugs, supplements, and herbals. Next, was the identification of PIMs, PPOs, and other
medications to consider for discontinuation or modification of current dosage. The questions
asked to evaluate medications in this step included: did the patient have a medical indication for
the drug; was the patient experiencing adverse effects; did potential harm outweigh benefits; did
the medication provide therapeutic efficacy; and what were patient preferences. Finally, the
determination of medications to discontinue or change was made based on the previous criteria,
the plan for stopping/changing medications was initiated, and monitoring support was provided
in follow-up. This deprescribing framework was generally employed in the research, to varying
degrees, initiated by a prescribing provider, a multidisciplinary team of health care professionals,
or a pharmacist medication review with recommendations to prescribers. Consultation with the
patient or a family member for input and preferences was also performed in some of the studies.
There were several methods or interventions used to identify the PIMs, PPOs and other
medications to discontinue or modify. Included in these methods were the STOPP/START
criteria, the American Geriatrics Society Beers Criteria, targeting specific drug classes (e.g.
NSAIDs, benzodiazepines, diuretics, antidepressants, and neuroleptics), educational programs
for prescribers and/or patients, and computer decision support systems. The studies
demonstrated these diverse methods to have various degrees of success in reducing
polypharmacy through deprescribing. But, not all methods studied were equally sensitive for the
identification of PIMs and PPOs.
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The majority of the literature indicates the reduction of polypharmacy and PIMs can
decrease the risk of adverse events in elderly persons. Among the negative consequences of
polypharmacy are reduced ability to perform daily tasks, increased risk for cognitive impairment,
delirium, falls, and urinary incontinence. The research suggested the more medications a person
uses regularly, corresponded with increased risk of drug interactions, emergency department
visits, hospital readmissions, and a rise in mortality. When measured, the studies imply an
improved quality of life experienced with the reduction of polypharmacy and PIMs. There was a
wide variation in the measurement of adverse effects and positive outcomes, with multiple
methods utilized to measure outcomes among the studies. Evaluating the body of literature,
multiple study outcomes were found positively affected by interventions used to deprescribe.
Successful managing polypharmacy, realizes patient and family participation is an
important component. Patients may pressure providers to continue prescribing certain
medications or a specific dosage, without a clear communication of medication changes. Often
patients don’t understand why they are on certain mediations, the reasons for a medication have
resolved, or recognize a medication as the cause of an undesired side effect. When patients or
family were educated and actively involved in the deprescribing process, the results reflect
improved understanding of medication changes and a significant decrease in polypharmacy.
Acknowledging that physicians, nurse practitioners, and physician assistants are the
primary care prescribers in the US, it follows the use of evidence-based deprescribing
interventions in the primary care settings is crucial to addressing polypharmacy, PIMs, and
PPOs. Prescribing clinicians in all disciplines perceive medication management and the ability
to address polypharmacy as vital skills for current and future practice. The literature
demonstrated that evidence-based deprescribing protocols incorporated into the primary care
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setting is an effective method for continuing development of clinical judgment and clinician
confidence necessary for appropriate prescribing and deprescribing of patient medications.
Several methods for deprescribing were represented in the research and preferences by clinicians
were shown to be relevant, focused and concise, user-friendly, evidence-based clinical tools.
Conceptual Framework
The conceptual framework used to guide the scholarly project was the Iowa Model of
Evidence Based Care (Iowa Model Collaborative [IMC], 2017). Permission was obtained from
the University of Iowa Hospitals and Clinics as evidenced by materials contained in Appendix A.
Adherence to the elements of the Iowa Model of Evidence Based Care ensured the successful
implementation of the scholarly project. The components addressed using the Iowa Model
(IMC, 2017) were the identification of problems and triggers; the purpose of the intervention in
addressing the phenomenon of interest; ensuring the topic was a priority to the organization;
assembling a project team; the literature search and research critique supported the project; the
development and implementation of the project; facilitated integration into practice change as
appropriate; and dissemination of results.
Triggers.
Research showed polypharmacy contributed to frequent readmissions to the hospital,
increased length of stay, adverse drug effects, risk of falls, physical and cognitive dysfunction,
and mortality (Masnoon et al., 2017; Muth et al., 2018). Evidence depicted clinicians at all
levels of practice in need of methods to improve management of polypharmacy and competency
in deprescribing (Djerbib, 2018; Farrell et al., 2018; Kostas et al., 2014; Mecca et al., 2019). The
research for the project has demonstrated the need for evidence-based guidelines in primary care
clinics to improve polypharmacy management.
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Purpose.
The purpose of the project was to evaluate the effects the an evidence-based deprescribing
tool had on prescribing clinicians’ confidence to address polypharmacy, PIMs, and PPOs in the
primary care setting. The intervention supported the decision-making process to perform
appropriate prescribing and deprescribing activities. The project increased skills and
competency in the clinicians’ abilities to address polypharmacy and deprescribing.
Organizational priority.
The mission statement for Hillsdale Community Hospital (HCH) is “to provide quality,
compassionate healthcare throughout the communities we serve” (Hillsdale Hospital [HH],
2019). The organizational values statement of HCH is “our commitment to you is Service
Excellence... where the patient always comes first” (HH, 2019). The scholarly project aligns
with the mission and values of the organization with continued improvement in primary care
through research-based methods, resulting in increased quality of care with a patient-centered
experience.
Formation of the team.
The next step in the Iowa Model of Evidence Based Care (IMC, 2017) is the formation of a
project team. The team for the project is the project leader, the outpatient clinical coordinator for
the hospital, clinical administrators, and the medical directors of the outpatient clinics. This is
the core group who made initial and ongoing decisions related to the project.
Evaluation process and pilot.
The Iowa Model of Evidence Based Care (IMC, 2017) next stage is the assembly, appraisal
and synthesize of the body of evidence. The evaluation of literature, found in Appendix B,
provided evidence to support the scholarly project. The literature review acknowledges the
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problem of polypharmacy, use of clinical guidelines for reduction of polypharmacy, the need for
medical management to address polypharmacy and deprescribing in the primary care setting, and
the value of evidence-based deprescribing protocol in improving skills and confidence of
prescribing clinicians. The scholarly project was a pilot program to analyze the effectiveness of
an evidence-based deprescribing tool on the clinicians’ perceived awareness and confidence to
initiate medications changes. The evaluation tool utilized was a pre-post survey of the
prescribing providers that measured confidence levels in recognition of polypharmacy and
decision-making in deprescribing.
Summary
The literature supported the use of deprescribing to address the problem of polypharmacy
in the elderly population. Although not consistent throughout, the majority of the literature
found an association between deprescribing and decreased risk of drug interactions, adverse
events, emergency department visits, hospital readmissions, and patient mortality. When
measured, most of the research validated deprescribing resulted in better patient outcomes.
Methods that focused on reduction of PIMs demonstrated the most effective approaches to
deprescribing and addressing issues related to polypharmacy.
The importance of appropriate prescribing and evidence-based interventions that address
polypharmacy were both topics shown to be important to prescribing clinicians of all disciplines
(Farrell et al., 2018; Kostas et al., 2014; Mecca et al., 2019). The research supported the need in
various settings to implement protocols developed for evaluating polypharmacy and PIMs, that
build knowledge, skills, competency, and confidence for deprescribing (Farrell et al., 2018;
Kostas et al., 2014; Mecca et al., 2019). Preferred methods were clinical tools that focus on userfriendly and relevant material (Djerbib, 2018). The evidence obtained through the literature
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review supports the scholarly project, which is the implementation of a deprescribing protocol to
improve skills and confidence in recognition of polypharmacy with the ability to make decisions
to address deprescribing.
Methodology
Design
The proposed scholarly project was an evidence-based practice, pilot project using the Iowa
Model of Evidence Based Care (IMC, 2017). The design of the project was a quasi-experimental
approach with an evidence-based polypharmacy protocol designed to assist prescribing clinicians
in the identification of PIMs and PPOs, and appropriate prescribing and deprescribing during
primary care visits in the outpatient clinic setting. The quasi-experimental design, although with
limitations, was the design preferred when it is not ethical or logistically feasible to conduct a
randomized control trial (Harris, McGregor, Perencevich, & Furuno, 2006).
All participants received the deprescribing tool to be utilized during clinic visits with
patients. The goal of the project was to improve primary care providers’ confidence in
addressing polypharmacy, PIMs and PPOs in the outpatient clinic setting. The quasiexperimental design planned, even with limitations, was expected to demonstrate a causal
association between the intervention and outcomes.
Measurable Outcomes
After the receiving the deprescribing protocol and utilizing it with patients, prescribing
clinicians were expected to demonstrate an increase in confidence rating on the Clinician
Polypharmacy Management Survey (CPMS), after a 4 week period. When comparing presurvey and post-survey scores, it was anticipated there would be a 10% increase in the
prescriber's confidence for the deprescribing decision-making process to reduce polypharmacy.
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The self-evaluation of the clinicians’ confidence in recognizing PIMs and PPOs was expected to
reflect a 15% increase in the post-test. The confidence ratings for the seven different barriers
were anticipated to show variable increases when post-survey scores are compared to pre-survey.
Setting
The project setting was several outpatient clinics located in Hillsdale County, Michigan.
The clinics are either owned by or closely associated with HCH. The HCH health system serves
the residents of Hillsdale and surrounding counties, with a wide range of inpatient and outpatient
services. The vision statement of HCH states, “As a leader in health services, HCH encompasses
all of your healthcare needs utilizing state-of-the-art technology while embracing a future of
organizational growth”, and the motto is “Large enough to be of service ... small enough to care”
(HH, 2019). The organization is committed to improving patient care and health through the
application of evidence-based practices. Providing patient-centered care, HCH serves a diverse
patient population, at all levels of the health and wellness spectrum. The letters of support in
Appendix C, D, and E confirms organizational support for the scholarly project.
Population
The population for the project was the HCH primary care clinic providers, comprised of
physicians, nurse practitioners, and physician assistants. All providers from the four primary
care clinics were invited to participate. In order to obtain additional participants, providers from
two primary care offices closely affiliated with the HCH were also invited to join the project.
There were a total of 15 possible participants. The inclusion criterion was the clinician must
have provided primary care at least 20 hours a week. The exclusion criterion was voluntarily
choosing not to participate in the project. Completion of the informed consent form and preintervention CPMS were required for participation in the project. An example of the informed
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consent form can be found in Appendix F. The participants were assigned a random code to
ensure confidentiality of information. The name-code key was stored in a locked, fireproof safe,
off-site.
Ethical Considerations
The Collaborative Institutional Training Initiative (CITI) training modules for human
research ethics and compliance training available on the Liberty University Institutional Review
Board (IRB) website have been completed by the project leader. Certificates confirming
completion can be found in Appendix G. It is important before conducting any research studies
involving human subjects, the researcher has received training to ensure an ethically designed
scholarly project and the protection of the human participants involved. The scholarly project
was presented and approved by the assigned Liberty University project chair and the
organizations invited to participate. The project was submitted to the Liberty University IRB,
and the IRB letter confirming project approval can be found in Appendix H. Evaluation of the
scholarly project by the IRB is vital to ensure the research is ethically acceptable, protects the
rights and privacy of the participants involved, and is in compliance with federal regulations and
laws.
Information gathered through the CPMS tool was stored in an Excel spreadsheet coded
only by the random number initially assigned to the participant, with no other identifying
information. The spreadsheet was password protected in addition to being stored on a laptop
with password protection. The surveys and informed consents were stored in a locked, fireproof
safe. Only the project leader has access to the spreadsheet and locked safe. The surveys,
informed consents, and name-number key will be destroyed three years after completion of the
project.
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Data Collection and Survey Tool.
Basic demographic data was collected during the initial pre-intervention survey and
includes clinic, professional title (physician, nurse practitioner, physician assistant), years in
practice and practice setting (primary care or other). The project leader developed the CPMS
tool based on the clinical question and barriers to deprescribing identified in the review of
literature (Djerbib, 2018; Farrell et al., 2018; Kostas et al., 2014; Mecca et al., 2019). The
purpose of the 10-item survey was to capture the participants’ perception of confidence when
deprescribing to reduce polypharmacy, recognizing PIMs and PPOs, and confidence when faced
with seven common barriers to deprescribing. A 0-10 scale was utilized for each question in the
CPMS tool to offer the participants a more precise definition of confidence level. The survey
was reviewed with other members of the project team to assure clarity of content, improving
reliability, and validity.
Participants completed the pre-intervention survey before the initial training on the use of
the deprescribing protocol tool and distribution of the tool. The survey took less than 10 minutes
to complete by all participants. The post intervention survey was distributed to the participants
via email, four weeks after receiving the deprescribing protocol tool and returned to the project
leader through return email. The pre-survey and post-survey results were entered into the IBM
SPSS Statistics 25 (IBM Corp., 2016) software for statistical analysis.
Intervention
The scholarly project intervention consisted of a polypharmacy protocol booklet and a brief
educational session designed to instruct the prescribing clinician on the use of the protocol. The
educational presentation took approximately ten minutes. The tool was an adaptation of the
STOPP/START toolkit using the following sources for current evidence-based information: the
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2019 American Geriatrics Society Beers Criteria®, UpToDate, and current practice guidelines
from the American Diabetes Association, the American College of Cardiology, the American
Heart Association, the Centers for Disease Control and Prevention, and the American College of
Chest Physicians. The final polypharmacy protocol booklet used in the scholarly project was a
series of double-sided, laminated cards approximately 5.25 x 4 inches, bound with a loose-leaf
ring in the upper left hand corner for ease of flipping to the desired information. Including the
reference information, there were a total of 6 flip cards composing the booklet.
Timeline.
The scholarly project action plan for the approval, initiation, implementation, and
evaluation of the scholarly project is contained in the following table.
Table 1. Scholarly Project Timeline
Action Item
Final scholarly project proposal submitted
Proposal Defense
Submitted to Liberty University IRB
IRB Approval
Visit clinics providing education, collect pre-intervention survey
data and distribute polypharmacy protocol
Start of data compilation
Final survey data collection complete
Statistical Analysis
Draft write up of scholarly project complete
Final write up of scholarly project complete
Send scholarly project to editor
Final defense PowerPoint completed
Final defense date
Complete final revisions and submit to Scholars Crossing
Disseminate information to stakeholders

Anticipated Completion
Date
10/25/2019
11/6/2019
11/8/2019
11/22/2019
Week of December 1st
12/16/2019
Week of January 6th
2/15/2020
2/17/2020
2/25/2020
2/25/2020
2/27/2020
3/12/2020
3/15/2020
3/26/2020
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Feasibility analysis.
The polypharmacy scholarly project has been successfully implemented at the HCH
primary care clinics and associated clinics. The project had the full support of the outpatient
clinics’ medical director, clinical coordinators and participating clinicians. The population of
Hillsdale County over the age of 65 is 18% compared to 15.9% for the State of Michigan (HH,
2019). This larger percent of elderly adults is associated with an increased incidence of chronic
disease and polypharmacy, providing the proper patient population for a successful
implementation.
The major cost of the project was the printing and materials used to produce the pocketsized polypharmacy protocol. Materials and printing were less than $100 and provided by the
project leader. There were minimal risks in the implementation of the polypharmacy protocol.
Use of the intervention did not replace the clinical judgment of the clinician and was initiated as
a supplement to the decision making process during patient medication review. There was
greater risk associated with not performing a medication review process that can decrease
polypharmacy and address the inappropriate prescribing of PIMs and PPOs. The overall analysis
of the scholarly project resulted in a neutral use of resources, increased confidence in primary
care clinicians with the deprescribing process, and expected improvement in patient outcomes
over time. These factors made the scholarly project very feasible for implementation.
Data Analysis
Following IRB approval, project implementation was initiated in the clinics, and also
marked the beginning of data collection for analysis. The general characteristics of the project
population were presented in a table format comprising the following information: clinic,
professional title (physician, nurse practitioner, physician assistant), years in practice and
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practice setting (primary care or other). Statistical analysis of the CPMS tool results was
produced utilizing IBM SPSS Statistics 25 (IBM Corp., 2019). The dependent variable was the
perceived awareness and confidence of the clinician to initiate medication changes to address
polypharmacy through deprescribing. The 10-question CPMS tool completed by clinicians,
before and after the intervention, measured the dependent variable. The independent variable
was the polypharmacy protocol booklet and a brief educational session. Only the participants
who completed the pretest and posttest CPMS tool were included in the data analysis.
The paired sample t-test was utilized to determine the effectiveness of the polypharmacy
intervention. The analysis examined the differences between pre-survey and post-survey results
obtained from the CPMS tool. Descriptive statistics included computed mean and standard
deviation to describe the project outcomes and were displayed in table format. Inferential
statistics included paired samples correlation and confidence interval. Inferential statistical
results for each outcome measure were displayed in table format.
Results
The scholarly project was designed to assess if an evidence-based protocol for
deprescribing increased clinician’s perceived awareness and confidence to address
polypharmacy, PIMs, and PPOs in an outpatient clinic population. Eight primary care providers,
from five clinics, accepted the invitation to participate in the polypharmacy project. The eight
participants (n=8) completed the pre-intervention survey, received the deprescribing tool, and a
brief training on how to use the tool in practice, at each clinic. The post-intervention survey was
sent to all eight participants by email four weeks after the office visits. The post-survey was
completed by seven participants (n=7), 87.5 % of the original participants, one participant (n=1)

POLYPHARMACY INTERVENTION

39

declined to complete the post survey, resulting in a non-completion rate of 12.5%. Table 1
displays the scholarly project participant numbers during the pre-survey and post-survey.
Table 2. Polypharmacy Intervention Participation by Pre-survey and Post-survey
Project Phase
Pre-Survey and Intervention
Post-Survey
Response Rate Post-Survey (%)

Completion
8
7
87.5

Non-completion
0
1
12.5

Descriptive Statistics
Only the seven participants who completed both the pre-intervention and post-intervention
surveys will be included in further data analysis. Originally, the demographic information of the
participants was to include clinic information. Due to the reassignment of some participants to
other clinics during the four weeks between the pre-survey and post-survey data collection, clinic
of practice became irrelevant as a demographic. The general characteristics of the project
population are displayed in Table 2.
Table 3. General Characteristics of Project Participants
Variable
Professional Title
Physician
Nurse Practitioner
Physician Assistant
Years in Practice
< 5 years
5-15 years

Frequency

Percentage (%) *

1
4
2

14.3
57.1
28.6

3
2

42.9
28.6

2

28.6

6
1

85.7
14.3

> 15 years
Practice Setting
Primary Care
Primary Care and Walk-in Clinic
*Response totals do not equal 100% due to rounding.
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In order to better understand clinician’s perceptions of polypharmacy and the deprescribing
tool, there were three standalone questions asked of each project participant. One question was
on the pre-intervention survey, asking if the clinicians perceived polypharmacy to be a major
health care issue in their practice setting. The other two questions were asked on the postintervention survey. The first question inquired if the clinician used the deprescribing tool, and
the second question, if the tool was helpful in the medication prescribing/deprescribing decisionmaking process. The majority of the clinicians, 85.7%, did perceive polypharmacy as a major
health care issue in the practice. One hundred percent of clinicians involved in the project did
use the deprescribing tool and all found it to be useful in the decision making process of
prescribing and deprescribing medications. Table 3 presents the results of clinicians’ responses.
Table 4. General Perception of Polypharmacy Prevalence and Use of Deprescribing Tool
Question
Pre-intervention
Perceive polypharmacy to be a
major health care issue?
Post-intervention
Did you use the deprescribing
tool?
Was the tool helpful in the
prescribing process?

Yes

Percentage (%)

No

Percentage (%)

6

85.7

1

14.3

7

100

0

0

7

100

0

0

The statistical analysis of the CPMS was performed utilizing IBM SPSS Statistics 25 (IBM
Corp., 2019). The paired samples t-test was applied to compare the differences in the pre-survey
and post-survey scores for each of the ten questions answered by the participants. The results
presented in Table 4 are the statistical values for mean, standard deviation, and standard error
means.
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Table 5. Paired Samples Statistics Analysis Organized by CPMS Question
CPMS
Question No.
1
2
3
4
5
6
7
8
9
10

N

Mean

Mean
Std. Error

Standard
Deviation

Pre-survey
Post-survey
Pre-survey
Post-survey
Pre-survey
Post-survey
Pre-survey

7
7
7
7
7
7
7

7.43
8.00
8.14
8.43
7.29
7.71
5.43

.649
.577
.634
.528
.680
.778
.528

1.718
1.528
1.676
1.397
1.799
2.059
1.397

Post-survey
Pre-survey
Post-survey
Pre-survey
Post-survey
Pre-survey
Post-survey
Pre-survey
Post-survey
Pre-survey

7
7
7
7
7
7
7
7
7
7

6.00
5.00
5.14
6.43
7.14
7.29
7.43
6.43
6.57
5.29

.617
.535
.553
1.043
1.100
.680
.719
.751
.685
1.017

1.633
1.414
1.464
2.760
2.911
1.799
1.902
1.988
1.813
2.690

Post-survey
Pre-survey
Post-survey

7
7
7

5.57
6.71
7.14

.997
.918
.911

2.637
2.430
2.410

Measurable Outcomes
The paired sample correlations are displayed in Table 5. There is an individual analysis for
each of the ten questions in the CPMS. The strength of association between the pre-survey and
post-survey variables, in all ten questions, was shown to have a strong positive correlation, with r
values ranging from .886 to .984 and significance levels of .000 to .008.
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Table 6. Paired Samples Correlations by CPMS Question
CPMS
Question No.

N

Correlation (r)

Sig.

1
2
3
4
5
6
7

Pre-survey & Post-survey
Pre-survey & Post-survey
Pre-survey & Post-survey
Pre-survey & Post-survey
Pre-survey & Post-survey
Pre-survey & Post-survey
Pre-survey & Post-survey

7
7
7
7
7
7
7

.889
.966
.971
.950
.886
.924
.981

.007
.000
.000
.001
.008
.003
.000

8

Pre-survey & Post-survey

7

.984

.000

9
10

Pre-survey & Post-survey
Pre-survey & Post-survey

7
7

.983
.976

.000
.000

The main outcome expected from the intervention was an increase in the clinicians’
perceived confidence in the deprescribing decision making process. This outcome was measured
by question 1 on the CPMS, with a predicted increase of 10% from the pre-survey mean to the
post-survey mean. The pre-post mean difference for question 1 is -.571 (see Table 6). This
mean difference calculates to an increase of 7.7% using the pre-survey mean of 7.43 (see Table
2). Although there is an increase in confidence in the decision making process to deprescribe, it
is less than the 10% predicted. Further analysis of the Table 6 results for question 1 (t[7] = 1.922 with a df = 6, p = .103 and 95% CI [-1.299, .156]), demonstrates the mean difference of .571 is not statistically significant.
Two secondary outcomes expected of the project were an increase in clinicians’ confidence
in the identification of PIMs and PPOs. It was predicted the post-survey mean would
demonstrate a 15% increase compared to the pre-survey results. These outcomes were measured
by questions 2 and 3 on the CPMS respectively. Evaluating the identification of PIMs, a mean
difference of -.286 is found for question 2 (see Table 6). This mean difference reflects an
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increase of 3.5% using the pre-survey mean of 8.14 (see Table 2). The increase in ability to
identify PIMs is less than the 15% predicted. Additional analysis of Table 6 results for question
2 (t[7] = -1.549 with a df = 6, p = .172 and 95% CI [-.737, .166]), show the mean difference of .286 is not statistically significant. The identification of PPOs utilizes the mean difference of .429 from question 3 (see Table 6). The mean difference calculates as an increase of 5.9% when
using the pre-survey mean of 7.29 (see Table 2). This result, although demonstrating an
increased ability to identify PPOs is less than the 15% predicted. Further evaluation of Table 6
results for question 3 (t[7] = -2.121 with a df = 6, p = .078 and 95% CI [-.923, .066]), show the
mean difference of -.429 is not statistically significant.
The remaining questions on the CPMS measure the confidence level of clinicians when
encountering seven commonly identified barriers to deprescribing. It was anticipated these
secondary outcomes would reflect increased post-survey scores, but the results were expected to
be variable and no percentage of increase was predicted. The fourth question measured
confidence in ability to deprescribe when the clinician was not the original prescriber of a
medication. The analysis of question 4 (Table 6) shows a significant average difference
comparing pre-survey and post-survey scores (t[7] = -2.828 with a df = 6, and p = .030), and on
average a post-survey scores were .571 higher pre-survey scores (95% CI[-1.006, -0.77]).
Question 4 was the only measure on the CPMS tool to demonstrate statistical significance.
Survey questions 5-10 measured confidence level of deprescribing for clinicians in the
following situations, respectively: a specialist prescribed the medications, unsure why a
medications was started originally, medication is used to treat adverse effect of another
medication, the patient/patient’s family are resistant to change, medication is coupled to
performance indicators, and concern for adverse drug effects or withdrawal. The statistical
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analysis of these six questions did demonstrate increases in post-survey scores compared to presurvey scores. But as shown in Table 6 the increases are not statistically significant.
Table 7. Paired Differences by CPMS Question
CPMS
Question
No.

Std.

Std.
Error

95% Confidence
Interval

Sig.

Pre-Post
1
2

Mean
-.571
-.286

Deviation
.787
.488

Mean
.297
.184

Lower
-1.299
-.737

Upper
.156
.166

t
-1.922
-1.549

df
6
6

(2-tailed)
.103
.172

3
4
5
6
7
8
9
10

-.429
-.571
-.143
-.714
-.143
-.143
-.286
-.429

.535
.535
.690
1.113
.378
.378
.488
.535

.202
.202
.261
.421
.143
.143
.184
.202

-.923
-1.066
-.781
-1.743
-.492
-.492
-.737
-.923

.066
-.077
.495
.315
.207
.207
.166
.066

-2.121
-2.828
-.548
-1.698
-1.000
-1.000
-1.549
-2.121

6
6
6
6
6
6
6
6

.078
.030
.604
.140
.356
.356
.172
.078

Discussion
Implication for Practice
The prevalence of polypharmacy within the healthcare system harms patient outcomes and
costs patients and healthcare institutions tens of millions of dollars yearly (Masnoon et al., 2017;
Quinn & Shah, 2017). Polypharmacy, PIMs, and PPOs effect up to 50% of the elderly
population and patients with two or more chronic diseases (Kua, 2019). The clinicians involved
in the project confirmed that polypharmacy was a major healthcare issue within the multiple
practice settings. The need for solutions to address polypharmacy through increased awareness
and confidence of clinicians is an important subject for improvement of healthcare. The findings
of this project are consistent with the research indicating the need to address polypharmacy in
everyday practice with the individual patient.
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Decreasing polypharmacy through appropriate medication management involving clinician
education and up-to-date evidence-based practice guidelines for prescribing and deprescribing in
the practice setting, is supported by the literature (Djerbib, 2018; Kostas et al., 2014; Martin et
al., 2018). In the research, guidelines addressing polypharmacy frequently followed a specific
framework and utilized a deprescribing protocol that was based on one or more of the many
evidence-based prescribing guidelines (Campins et al., 2017; Clyne et al., 2016; Kua et al., 2019;
Martin et al., 2018; Urfer et al., 2016; Van der Linden et al., 2017). The polypharmacy protocol
developed and used in the scholarly project was based on the proven framework and
incorporated the most up-to-date evidence-based prescribing and deprescribing guidelines. The
protocol tool was designed with the intention for ease of use in the outpatient clinical
environment. All of the clinicians involved in the project used the polypharmacy protocol for
prescribing and deprescribing in their practice. In addition, all of the clinicians found the tool
was helpful in the decision-making process of prescribing and deprescribing medications. The
project findings reinforced the importance of well designed, polypharmacy protocols based on
evidence-based guidelines that is found in literature.
Clinician education and evidence-based practice guidelines that focus on proper prescribing
and deprescribing, have been shown in the research to improve awareness of polypharmacy and
increase confidence in clinicians at all levels of experience (Djerbib, 2018; Farrell et al., 2018;
Mecca et al., 2019). The qualities of awareness and confidence are important to the process of
addressing polypharmacy, including both inappropriately prescribed or omitted medications.
The 10-question CPMS tool was used to evaluate clinicians’ awareness and confidence by
comparing the results of the pre-post surveys. The analysis of the CPMS tool scores
demonstrated an increased overall awareness and confidence in all ten measures, although only
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one measure was found to be statistically significant. Even though not statistically signification
and two of the predicted outcome measures were not reached, it is clinically significant that
survey results revealed an increased confidence to reduce polypharmacy and ability to recognize
both PIMs and PPOs prescribed to patients. In addition, there was an increase in confidence
level to deprescribe in each of the following situations: not the original prescriber of the
medication, a specialist prescribed the medications, unsure why a medication was started
originally, medication is used to treat adverse effect of another medication, the patient/patient’s
family are resistant to change, medication is coupled to performance indicators, and concern for
adverse drug effects or withdrawal. The scholarly project demonstrated the effectiveness of the
evidence-based polypharmacy protocol for increasing the awareness and confidence of the
clinician in deprescribing.
The most notable limitation of the scholarly project was four of the seven participants had
the EPIC electronic health record in their practices. The alerts, performance indicators linked to
diagnoses, and clinical decision-making interfaces, all could have contributed to elevated selfevaluation scores on the CPMS, especially on the pre-survey, taken before the introduction of the
polypharmacy protocol tool. The possible cause of an elevation of the pre-survey scores would
have been related to the clinician’s confidence in EPIC’s ability to identify PPOs and
contraindicated mediations. Falsely elevated confidence scores on the pre-survey could
potentially lead to post-survey confidence scores not representing the true increase. Further
studies could address this problem by introducing the polypharmacy protocol before the presurvey.
A second limitation is the small sample size of the scholarly project. The small sample
size, n=7, can decrease the power of the statistical analysis, reducing the confidence level of the
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project results. A small sample size can affect the generalizability to another population or the
repeatability in the same setting. The third limitation is the four weeks between the pre-survey
and the post-survey. If the clinicians were given a longer period of time to use the protocol,
three or six months, the results may have shown statistical significance (Farrell et al., 2018;
Mecca et al., 2019).
The limitations discussed are important. Although only one of the ten measures was
statistically significant and two of the three outcome measures were not met, the consistency of
clinically significant positive results demonstrated in all ten measures, shows an increase in
clinician confidence. This increase in confidence experienced by the clinicians may create
positive changes in practice with the potential to benefit both patients and the organizations
through an improved level of care in the outpatient clinics. The results of the project agree with
the literature that confidence to address polypharmacy can be increased through use of the
evidence-based guidelines (Djerbib, 2018; Farrell et al., 2018; Mecca et al., 2019).
Sustainability
The five clinics that participated in the project are owned my three different entities that are
either a part of, or associated with, HCH healthcare system. The medical directors, clinic
administrators, and participating clinicians have all expressed enthusiasm for the polypharmacy
protocol. The clinicians have also confirmed polypharmacy as a major healthcare issue within
the practices and community. Before the scholarly project proposal, addressing the substantial
problem of polypharmacy within the healthcare system and clinics was not a focal point for
improving patient care. The initiation of the polypharmacy intervention into the practices has
introduced an evidence-based solution for addressing polypharmacy beyond the scope of the
electronic health records.
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Evaluation of the scholarly project outcomes has provided information on the statistical and
clinical significance of the polypharmacy protocol. This information will be shared with the
medical directors, clinic administrators, and participating clinicians. This group will need to
determine if the protocol is appropriate for integration across the clinics, or the current
participating clinicians will continue using the tools. The adoption of the intervention can be
implemented with very limited resources. These costs would include a yearly update to the tool
utilizing the latest evidence-based guidelines and associated reprinting cost.
Dissemination Plan
The use of evidence-based guidelines for development of interventions to address
polypharmacy, PIMs, and PPOs is supported by the critical appraisal of the literature. The
evaluation of the scholarly project by the medical directors, clinic administrators, and
participating clinicians will determine the sustainability of the interventions and moving forward
with the proposed execution of the dissemination plan. If the decision is to move forward with
further introduction and integration into the clinics, the project leader will partner with the clinic
administrators to complete this task. The project leader will present the polypharmacy protocol
booklet with a brief educational session designed to instruct the prescribing clinicians on use of
the protocol. This introductory session will be completed at any additional clinics where the
intervention is implemented. If the clinic administrators wish to continue collecting data, the
CPMS tool and Excel spreadsheet templates will be provided with documentation on usage. The
word document containing the polypharmacy protocol will be shared with the organization and
training will be offered for maintaining the protocol with future evidence-based guidelines. The
completed, final scholarly project write-up will be published electronically in Liberty
University’s Scholars Crossing.
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The challenges encountered by this project leader while working on the scholarly project
have been numerous. Looking to our Father in Heaven, has sustained this project leader through
this process. Two Bible verses have helped with perseverance and served as a reminder of why
this student is a nurse and importance of pursuing a DNP. Philippians 2:4 (New International
Version), “Do not merely look out for your own person interests, but also for the interests of
other” and Galatians 6:2 (New International Version), “Bear one another’s burdens, and thereby
fulfill the law of Christ”.
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Article Title,
Author, etc.
(Current APA
Format)

Campins, L.,
Serra-Prat, M.,
Gózalo, I.,
López, D.,
Palomera, E.,
Agustí, C., . . .
on behalf of the
REMEI Group.
(2017).
Randomized
controlled trial
of an
intervention to
improve drug
appropriateness
in communitydwelling
polymedicated
elderly people.

Study
Purpose

To assess the
effectiveness
and safety of
implementing
a medications
evaluation
using the
STOPP/
START tools.
The study is
for elderly
persons living
in the
community,
with
polypharmacy
of 8 or more
medications.

Sample
(Characteristi
cs of the
Sample:
Demographics
, etc.)
A convenience
sample of 503
recruited
elderly patients
within the
community, 70
years of age or
older taking 8
or more
medications.

Methods

Study Results

Randomized,
open-label,
multicenter,
parallel-arm
clinical trial
with followup.

Findings
indicate 26.5%
of prescriptions
were
potentially
inappropriate
and 21.5%
were changed.
There was at
least one
change in
95.6% of the
intervention
group. The
mean number
of prescription
per patient was
significantly
lower at 3, 6,
and 12 months
when
compared to

Level of
Evidence
(Use Melnyk
Framework)

Level 2:
randomized
controlled
trial

Study
Limitations

Results were
not evaluated
blind. Possible
interventionto-control
contagion, as
the same
physicians had
patients in each
arm of the
study. Sample
size has limited
statistical
power for the
secondary
outcomes.

Would Use as
Evidence to
Support a
Change?
(Yes or No)
Provide
Rationale.
Yes,
evaluation of
polypharmacy
using an
effective tool
can
successfully
and safely
reduce the
burden and
cost of
polypharmacy
to the patient.
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Clyne, B.,
Cooper, J. A.,
Hughes, C. M.,
Fahey, T.,
Smith, S. M.,
OPTI-SCRIPT
study team, &
on behalf of the
OPTI-SCRIPT
study team.
(2016). A
process
evaluation of a
cluster
randomized

Study
Purpose

To explore
intervention
execution,
effectiveness,
and preference
of a threephase
intervention to
reduce
inappropriate
prescribing for
the elderly in
a primary care
setting.

Sample
(Characteristi
cs of the
Sample:
Demographics
, etc.)

A purposive
sampling to
ensure
coverage of 21
GP practices
and
heterogeneity
of the 196
elderly patient
participants.
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Methods

A cluster
randomized
control trial
employing
mixed
method
analysis with
quantitative
data as well
as semistructure
interviews.

Study Results

the control
group. No
differences in
number of
emergency
room visits,
hospitalizations
, and deaths
were observed.
Intervention
delivery varied
among the GP
practices with
just over 70%
of practices
completing the
medication
review as
recommended
with patient
present.
Changes to
medication
regimen were

Level of
Evidence
(Use Melnyk
Framework)

Level 2:
randomized
controlled
trial

Study
Limitations

Study
limitations
focused on
qualitative
data: which
was limited by
availability of
participants as
well as
restrictive time
allocated to the
interviews.

Would Use as
Evidence to
Support a
Change?
(Yes or No)
Provide
Rationale.

Yes, the
research
shows
interventions
aimed to
decrease the
number of
inappropriate
prescribed
medications
in the elderly
is effective
and
achievable; it
also
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Methods

Study Results

A
longitudinal
preintervention
and postintervention
experimental

more
successful with
patients
present.
Patient
information
leaflets were
not used
employed by
any GP
practice. Both
GPs and
patients viewed
the OPTISCRIPT
intervention
positively.
An absolute
decrease of
PIMs usage of
3.5%.
Interventions
included:
distribution of

trial to reduce
potentially
inappropriate
prescribing in
older people in
primary care
(OPTI-SCRIPT
study).

Cossette, B.,
Bergeron, J.,
Ricard, G.,
Éthier, J.,
Joly‐Mischlich,
T., Levine, M.,
. . . Brazeau, S.

Evaluate the
effects of a
multiple
interventions
strategy on the
prescribing
behavior of

A convenience
sample of 8622
patients, aged
75 and older
discharged
from the
hospital in

Level of
Evidence
(Use Melnyk
Framework)

Study
Limitations

Would Use as
Evidence to
Support a
Change?
(Yes or No)
Provide
Rationale.
reinforces the
importance of
patient
participation.

Level 3:
quasiexperimental
design

Implementatio
n of multiple
interventions at
different time
points did not
allow effects to
be tracked

Yes, this
research
identifies
successful
interventions
used for the
decreasing
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Methods

(2016).
Knowledge
translation
strategy to
reduce the use
of potentially
inappropriate
medications in
hospitalized
elderly adults.

health
professional.
Each
individual
intervention
has been
shown to be
effective in
research
literature.

2013-2014.

design.

Djerbib, A.
(2018). A
qualitative
systematic
review of the
factors that
influence
prescribing
decisions by
nurse
independent

Establish and
understand the
dynamics that
influence the
prescribing
decisionmaking
process of
primary care
nurse
independent

The sample is
10 qualitative
research
studies of
independent
nurse providers
in the primary
care setting,
who regularly
prescribe as
part of patient

A systemic
review of
qualitative
research
studies
matching the
inclusion
criteria of
nurse
independent
prescribers,

Study Results

educational
material,
presentation to
targeted
clinician
groups,
pharmacist
presentations,
computerized
alerts, and
comprehensive
geriatric
assessment.
Three major
themes
emerged. The
first two
themes are
perception of
competence
and perception
of risk. Needs
identified to
increase

Level of
Evidence
(Use Melnyk
Framework)

Level 5:
qualitative
systemic
review

Study
Limitations

separately.
Lack of home
medication
lists. Effect on
clinical
outcomes not
measured.
Study was 8
months and
limits the
evaluation of
long-term
effects.
There was not
a second
reviewer to
reduce the risk
of bias and
improve
transparency.

Would Use as
Evidence to
Support a
Change?
(Yes or No)
Provide
Rationale.
PIMs in the
elderly patient
in the
hospital.

Yes, this
research
identifies the
areas of
perceived
competence
and risk as
influential in
the
prescribing of
independent
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prescribers in
primary care.

providers.

care.

Farrell, B.,
Richardson, L.,
Raman-Wilms,
L., de Launay,
D., Alsabbagh,

Determine
whether the
implementatio
n of
deprescribing

A convenience
sample,
participants
were
physicians,
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Methods

Study Results

competence
and comfort
level include:
knowledge,
skills,
education and
training,
experience, and
evidence-based
guidelines and
protocols. The
third theme is
impact on
patient,
involving
patient
adherence,
medical need,
and costs.
A
Longitudinal
longitudinal
data showed
pre-post
the profound
deprescribing increase in selfself-efficacy efficacy where

Level of
Evidence
(Use Melnyk
Framework)

Study
Limitations

primary care,
prescribing
decisionmaking,
peerreviewed and
studies
performed in
the United
Kingdom.

Would Use as
Evidence to
Support a
Change?
(Yes or No)
Provide
Rationale.
nurse
providers. It
recognizes
knowledge,
education, and
evidencebased
guidelines as
methods used
to improve
competence.
Finally, it
considers the
impact of
prescribing on
patients.

Level 3:
quasiexperimental
design

Low number of
survey
respondents
and lack of
psychometric

Yes, this
study shows
the use of
evidencebased

POLYPHARMACY INTERVENTION

Article Title,
Author, etc.
(Current APA
Format)

M. W., &
Conklin, J.
(2018). Selfefficacy for
deprescribing:
A survey for
health care
professionals
using evidencebased
deprescribing
guidelines.
Fried, T. R.,
O'Leary, J.,
Towle, V.,
Goldstein, M.
K., Trentalange,
M., & Martin,
D. K. (2014).
Health
outcomes
associated with
polypharmacy
in

Study
Purpose

Sample
(Characteristi
cs of the
Sample:
Demographics
, etc.)

61

Methods

Study Results

guidelines
would change
the perception
of selfefficacy of the
clinician.

nurse
practitioners,
and
pharmacists
from 3 longterm cares and
3 family health
teams. Total
participants =
50.

survey in a
quasiexperimental
design.

guidelines were
routinely used.

Summarize
health
outcomes
associated
with
polypharmacy
in elderly
communitydwelling
persons.

The sample is
50
observational
research
studies of
elderly persons
in the
community.
The majority of
the studies are
identified as
cross-sectional

A systemic
review of
selected
observational
research
studies.

When
polypharmacy
was 4 or more
medications
there was more
likely to be an
association
between
measured
outcomes and
polypharmacy.
Although

Level of
Evidence
(Use Melnyk
Framework)

Level 4:
Cohort
studies (there
is not a higher
level of
evidence
using Melnyk
for a systemic
review of
cohort/casecontrol
studies)

Study
Limitations

Would Use as
Evidence to
Support a
Change?
(Yes or No)
Provide
Rationale.

testing of the
instrument.

guidelines in
deprescribing
increase
confidence
and selfefficacy.

Heterogeneity
in study
populations
and the
definition of
polypharmacy
between
studies made
direct
comparisons
challenging.
Many of the

Yes, although
there is a lot
of
heterogeneity
between the
studies, the
association
between
polypharmacy
and negative
health
outcomes is

POLYPHARMACY INTERVENTION

Article Title,
Author, etc.
(Current APA
Format)

Study
Purpose

or longitudinal
cohort studies
with 4 casecontrol studies.

community‐dw
elling older
adults: A
systematic
review.

Kimura, T.,
Ogura, F.,
Yamamoto, K.,

Sample
(Characteristi
cs of the
Sample:
Demographics
, etc.)

The efficacy
of an
assessment

A convenience
sample of 822
inpatients aged

62

Methods

Study Results

results and
outcomes
studied varied
per study, the
majority of
studies
demonstrated
relationships
between
polypharmacy
and falls, fall
outcomes, fall
risk factors,
adverse drug
events,
hospitalization,
mortality,
measure of
function and
level of
cognition.
A
A total of 346
prospective
patients were
observational prescribed 1 or

Level of
Evidence
(Use Melnyk
Framework)

Study
Limitations

studies were
found through
searching
study reference
lists; this may
indicate the
other relevant
studies were
missed. Some
of the studies
were broad in
medications
prescribed,
while others
were not
specific to
excluded or
included drugs
or drug classes.
Level 4:
cohort study

Would Use as
Evidence to
Support a
Change?
(Yes or No)
Provide
Rationale.
strong when
viewed in the
overall
context.

Study’s
Yes, the
generalizability research
limited by one shows the

POLYPHARMACY INTERVENTION

Article Title,
Author, etc.
(Current APA
Format)

Uda, A.,
Nishioka, T.,
Kume, M., . . .
Hirai, M.
(2017).
Potentially
inappropriate
medications in
elderly
Japanese
patients: Effects
of pharmacists’
assessment and
intervention
based on
screening tool
of older
persons’
potentially
inappropriate
prescriptions
criteria ver.2.
Komagamine,
J., & Hagane,

Study
Purpose

Sample
(Characteristi
cs of the
Sample:
Demographics
, etc.)

63

Methods

Study Results

and
intervention
by hospital
pharmacists
using the
STOPP
criteria related
to potentially
inappropriate
prescriptions
(PIMs) in
elderly
patients.

65 or older.

study from
more PIMs,
April 2015 to 310 PIMs were
March 2016. recommended
to be
discontinued,
with a total of
292 PIMs
discontinued or
changed related
to the
intervention.

Evaluate the
effectiveness

A convenience
sample of 164

A
retrospective

The total
number of

Level of
Evidence
(Use Melnyk
Framework)

Level 4:
correlational

Study
Limitations

Would Use as
Evidence to
Support a
Change?
(Yes or No)
Provide
Rationale.

study site and
the prescribing
of PIMs drug
classes may
vary in
different
countries.
Change in
patient
outcomes with
use of the
STOPP criteria
was not
evaluated.
Reason for
initial
prescribing of
PIM was not
considered in
intervention.

prescribing of
PIMs is a
significant
problem in the
elderly, which
needs to be
addressed.
The research
also found
PIMs can
effectively be
addressed
using tools
that are
currently
available.

The setting
was a single

Yes, the
intervention

POLYPHARMACY INTERVENTION

Article Title,
Author, etc.
(Current APA
Format)

K. (2017).
Intervention to
improve the
appropriate use
of
polypharmacy
for older
patients with
hip fractures:
An
observational
study.

Study
Purpose

of an
intervention to
improve
appropriate
polypharmacy
for elderly
patients
admitted to
the hospital
for hip
fractures.

Sample
(Characteristi
cs of the
Sample:
Demographics
, etc.)

64

Methods

Study Results

patients
observational potentially
admitted to the study.
inappropriate
hospital for a
medications at
hip fracture
discharge was
over a two-year
significantly
period. All
lower in the
were 65 years
intervention
of age or older
group
and prescribed
compared to
5 or more
the control
medications at
group. No
admission.
significant
differences
were observed
in clinical
outcomes, at
the 6-month
follow-up,
when
comparing
intervention
control groups.

Level of
Evidence
(Use Melnyk
Framework)

design cohort study

Study
Limitations

site.
Observational
study not a
randomized
controlled trial.
Database
information
was used, with
no direct
contact with
patient. Those
lost to followup was high.
Long-term
outcomes are
unknown.
Adverse
reactions to
medications
changes are not
recorded.

Would Use as
Evidence to
Support a
Change?
(Yes or No)
Provide
Rationale.
was
successful in
lowering the
number of
medications
in the control
group. Other
studies have
shown
improvements
in multiple
outcomes that
were not
measured in
this study.
Only looking
at a special
subset of
patients for
the
intervention
may dilute the
real effect of
the

POLYPHARMACY INTERVENTION

Article Title,
Author, etc.
(Current APA
Format)

Study
Purpose

Sample
(Characteristi
cs of the
Sample:
Demographics
, etc.)

65

Methods

Kostas, T.,
Zimmerman,
K., Salow, M.,
Simone, M.,
Whitmire, N.,
Rudolph, J. L.,
& McMahon,
G. T. (2014).
Improving
medication
management
competency of
clinical trainees
in geriatrics.

Evaluation of
workshop that
improves
medical
trainees ability
to perform
accurate
medication
reviews that
result in
positive
changes in the
management
of patients’
medication
regimens.

A convenience
sample of
internal
medicine
residents,
physician
assistant
students, and
geriatric
fellows. Total
of 76
participants in
the workshop
and follow-up.

Quasiexperimental,
before-after
intervention
design, with
survey

Kua, C., Mak,
V. S. L., &
Huey Lee, S.
W. (2019).
Health
outcomes of

Evaluate
deprescribing
studies
performed
among the
elderly

The sample is
41 randomized
clinical studies
conducted in
nursing homes
on elderly

A systematic
review and
metaanalysis of
randomized
control trials

Study Results

The medication
management
workshop
improved
medical
trainees’
ability to
accurately
perform
medication
review and
ability to make
appropriate
medications
changes using
deprescribing
protocols.
Medication
review with
directed
deprescribing
had significant
benefits.

Level of
Evidence
(Use Melnyk
Framework)

Study
Limitations

Level 3:
quasiexperimental
design

The study
design did not
include a
control group.
Conducted at a
single site.
Low
participation
rate for the
follow-up
survey.

Level 1:
systemic
review and
meta-analysis
of
randomized

Measureable
clinical
outcomes in
areas such as
falls and
mortality in

Would Use as
Evidence to
Support a
Change?
(Yes or No)
Provide
Rationale.
intervention.
Yes, medical
trainees in
multiple
disciplines
were able to
identify
appropriate
medications
for
deprescribing
and make
changes in the
clinical
setting with
the lessons
learned in the
workshop.
Yes,
deprescribing
was found to
be an
effective
approach to

POLYPHARMACY INTERVENTION

Article Title,
Author, etc.
(Current APA
Format)

Study
Purpose

Sample
(Characteristi
cs of the
Sample:
Demographics
, etc.)

deprescribing
interventions
among older
residents in
nursing homes:
A systematic
review and
meta-analysis.

residents in
patients
nursing homes
and the
resulting
clinical
outcomes.

Martin, P.,
Tamblyn, R.,
Benedetti, A.,
Ahmed, S., &
Tannenbaum,
C. (2018).
Effect of a

Compare the
effect of a
pharmacistled
educational
intervention
versus

There were 69
community
pharmacies
with a total of
489 recruited
patients, aged
65 or older.

66

Methods

A pragmatic,
clusterrandomized
clinical trail,
with the
pharmacy
used as the

Study Results

Level of
Evidence
(Use Melnyk
Framework)

Overall
deprescribing
interventions
reduced by
59% the
number of
potential
inappropriate
medications.

controlled
trials

At the six
months, 43%
of the
intervention
group was no
longer
receiving

Level 2:
randomized
controlled
trial

Study
Limitations

several studies,
limited the
study’s ability
to pool data
and conduct
meta-analysis.
Many studies
had short study
periods and
absence of
blinding.
There were
also variations
in reporting
measures for
the same
outcome.
Limited
recruitment of
patient using
NSAIDs and
1st generation
antihistamines.
Guidelines

Would Use as
Evidence to
Support a
Change?
(Yes or No)
Provide
Rationale.
reducing
potentially
inappropriate
medications.
Also, the
methods in
this study did
not increase
risks to the
patients.

Yes, even
with the
limitations of
the study
education of
the patient
and primary

POLYPHARMACY INTERVENTION

Article Title,
Author, etc.
(Current APA
Format)

pharmacist-led
educational
intervention on
inappropriate
medication
prescriptions in
older adults:
The DPRESCRIBE
randomized
clinical trial.

Study
Purpose

standard care
for the
reduction of
inappropriate
prescriptions.
Community
dwelling older
adults and
their
physicians are
the focus of
the
intervention.

Sample
(Characteristi
cs of the
Sample:
Demographics
, etc.)
Each patient
was prescribed
one or more of
4 specific
Beers Criteria
medication
groups.

67

Methods

Study Results

unit of
randomizatio
n.

prescriptions
for the
inappropriate
medication(s)
compared with
12% of the
control group.
No adverse
events
requiring
hospitalization
were reported.

Level of
Evidence
(Use Melnyk
Framework)

Study
Limitations

changes for
treatment of
type 2 diabetes
calling for the
discontinuation
of glyburide,
was a
confounding
factor.
Pharmacists
were
inconsistent
distributing
evidence-based
information to
physicians. No
data collection
for adverse
effects not
requiring
hospitalization.
Reasons for
deprescribing
were not

Would Use as
Evidence to
Support a
Change?
(Yes or No)
Provide
Rationale.
care providers
is a consistent
theme in the
literature.
Also,
deprescribing
using the
Beers Criteria
has reliably
demonstrated
positive
patient
outcomes in
the literature.

POLYPHARMACY INTERVENTION

Article Title,
Author, etc.
(Current APA
Format)

Mecca, M. C.,
Thomas, J. M.,
Niehoff, K. M.,
Hyson, A.,
Jeffery, S. M.,
Sellinger, J., . . .
Brienza, R.
(2019).
Assessing an
interprofessiona
l polypharmacy
and
deprescribing
educational
intervention for
primary care
post-graduate
trainees: A
quantitative and
qualitative
evaluation.

Study
Purpose

Assess
internal
medicine and
nurse
practitioner
residents’
knowledge of
polypharmacy
and
perceptions of
the
interprofessio
nal education
intervention –
IMPROVE

Sample
(Characteristi
cs of the
Sample:
Demographics
, etc.)

Total residents
= 36, with 18
in the
intervention
group and 18 in
the control
group.
Veterans
receiving care
= 71. Study
performed in a
Veterans
Administration
polypharmacy
clinic.

68

Methods

Prospective
cohort
controlled
study without
randomizatio
n.

Study Results

Intervention
group had
significant
greater
improvement
on test scores,
perceived
improvement
in knowledge
and skills,
noting positive
change in
practice in the
clinical setting.
The average
number of
medications
discontinued
per veteran was
two.

Level of
Evidence
(Use Melnyk
Framework)

Level 3:
quasiexperimental
design

Study
Limitations

collected from
patients or
physicians.
Small number
of residents in
the study.
Selection bias.
Safety of
medication
discontinuation
long term was
not evaluated.

Would Use as
Evidence to
Support a
Change?
(Yes or No)
Provide
Rationale.

Yes, this
study is
consistent
with the
theme that
education for
deprescribing
of medical
trainees in
multiple
disciplines is
an effective
method to
reduce
polypharmacy
and the
importance of
precepting by
other
professional
to improve

POLYPHARMACY INTERVENTION

Article Title,
Author, etc.
(Current APA
Format)

Muth, C.,
Uhlmann, L.,
Haefeli, W. E.,
Rochon, J., van
den Akker, M.,
Perera, R., . . .
Harder, S.
(2018).
Effectiveness of
a complex
intervention on
prioritising
multimedicatio
n in
multimorbidity
(PRIMUM) in
primary care:
Results of a
pragmatic
cluster
randomised
controlled trial.

Study
Purpose

Investigate the
effectiveness
of a computer
decision
support
system in
general
practice for
improving
appropriately
prescribed
medication in
older patients
with multiple
morbidities.

Sample
(Characteristi
cs of the
Sample:
Demographics
, etc.)

From 72
general
practices in
Hesse,
Germany a
random
sampling of
505 cognitively
intact patients,
60 years of age
or older, 3 or
more chronic
diagnoses
requiring 5 or
more long-term
drug
prescriptions.

69

Methods

A pragmatic,
cluster
randomized
control trial.
Unit of
randomizatio
n was the
practice.

Study Results

Findings
indicate the
PRIMUM
intervention
had no
significant
effects patient
prescriptions,
functional
status, or
quality of life.

Level of
Evidence
(Use Melnyk
Framework)

Level 2:
randomized
control trial

Study
Limitations

Would Use as
Evidence to
Support a
Change?
(Yes or No)
Provide
Rationale.

care and build
confidence.
Definition of
Likely, in this
polypharmacy study group
was arbitrary.
there was
The study was already a high
population
quality of life
based and
and functional
response rate
status and
was low,
there were
limiting the
few
generalizability medications
of the study. It determined to
was felt the
be
outcome
inappropriate.
measures were This study is
more
still provides
insensitive
important
then expected. outcomes to
Because of the consider in
intense
the overall
collection of
scope of the
data at every
proposed
study visit, the project.

POLYPHARMACY INTERVENTION

Article Title,
Author, etc.
(Current APA
Format)

Pasina, L.,
Brucato, A. L.,
Falcone, C.,
Cucchi, E.,
Bresciani, A.,
Sottocorno, M.,
. . . Nobili, A.
(2014).
Medication
non-adherence
among elderly
patients newly
discharged and
receiving
polypharmacy.

Study
Purpose

Identify
adherence to
medication
regimen in
elderly
patients
identified with
polypharmacy
after hospital
discharge.

Sample
(Characteristi
cs of the
Sample:
Demographics
, etc.)

A convenience
sample of 100
patient aged 65
or older
recently
discharged
from an
internal
medicine ward
in Italy
throughout
2012.

70

Methods

Nonexperimental,
structured
telephone
interview.

Study Results

Non-adherence
to medication
regimens was
55.1% at first
follow-up (1530 days after
discharge) and
69.6% at 3month followup. Number of
drugs
prescribed at
discharge was
related to
medication
non-adherence.
Only 28.1% of
patients at the

Level of
Evidence
(Use Melnyk
Framework)

Level 6:
qualitative
study

Study
Limitations

risk of the
Hawthorne
effect was
potentially
higher than
normal.
Small sample
size. The selfreporting
method of the
interviews is
likely to lead
to
overestimation
of adherence.
Lack of
information
concerning
clinical
outcomes.

Would Use as
Evidence to
Support a
Change?
(Yes or No)
Provide
Rationale.

Yes, as it
provides good
data and
rational for
the
simplification
of drug
regimens and
the
importance of
patient
understanding
the reason for
each
medication
prescribed.

POLYPHARMACY INTERVENTION

Article Title,
Author, etc.
(Current APA
Format)

Potter, K.,
Flicker, L.,
Page, A., &
Etherton-Beer,
C. (2016).
Deprescribing
in frail older
people: A
randomised
controlled trial.
Schäfer, I.,
Kaduszkiewicz,
H., Mellert, C.,
Löffler, C.,
Mortsiefer, A.,
Ernst, A., . . .

Study
Purpose

Reduction in
the number of
medications
consumed by
people living
in a residential
aged care
facility.
Demonstrate
an
intervention
based on
patientcentered

Sample
(Characteristi
cs of the
Sample:
Demographics
, etc.)

A convenience
sample of 95
people over the
age of 65,
living in 4
residential aged
care facilities
in rural
Western
Australia
Randomly
selected
patients from
those who
accepted
invitations after

71

Methods

Study Results

A
randomized
control
study, in an
open trial
using a
parallel
design

first follow-up
and 25.3% at
the second
follow-up
understood the
reasons for
their
medications.
Findings show
of the 348
medications
targeted for
deprescribing,
207
medications or
59% were
successfully
discontinued.
There was no
difference
between the
control and the
intervention
groups related

A two-arm
clusterrandomized
control trial.

Level of
Evidence
(Use Melnyk
Framework)

Study
Limitations

Level 2:
randomized
controlled
trial

Small sample
size, an open
design that can
contribute to
treatment bias.

Level 2:
randomized
controlled
trial

There is a
slight patient
selection bias
regarding
gender and
specific

Would Use as
Evidence to
Support a
Change?
(Yes or No)
Provide
Rationale.

Yes,
deprescribing
in the frail
elderly can be
accomplished
without
adverse
affects and
health
outcomes.
Likely, but
valuable
information is
found in the
study. The
intensity of

POLYPHARMACY INTERVENTION

Article Title,
Author, etc.
(Current APA
Format)

Study
Purpose

Sample
(Characteristi
cs of the
Sample:
Demographics
, etc.)

Altiner, A.
(2018).
Narrative
medicine-based
intervention in
primary care to
reduce
polypharmacy:
Results from
the clusterrandomised
controlled trial
MultiCare
AGENDA.

communicatio
n will reduce
polypharmacy
in the patient
without
negatively
affecting the
quality of life.

meeting study
criteria, across
55 primary
care practices
in Germany for
a total sample
of 604 patients.
Age 65-84
years old with
at least three
chronic
diagnoses.

Snell, R.,
Langran, T., &

Investigate
patient views

The sample is
819 patients,

72

Methods

Study Results

Level of
Evidence
(Use Melnyk
Framework)

to a change in
number of
medications
taken or quality
of life
indicators. The
intervention
group was
twice as likely
to receive an
analgesic over
the course of
the study as
well as spend
fewer days in
the hospital.

A patient
feedback

The education
was found

Level 6:
qualitative

Study
Limitations

diagnosis
groups.
Compared to
the average
population,
volunteers may
have been
more
cooperative
and have a
higher
satisfaction
with their
primary care.
Consultations
were not
observed, so
intervention
implementatio
n may not have
followed the
protocol.
Only 51% of
the patient

Would Use as
Evidence to
Support a
Change?
(Yes or No)
Provide
Rationale.
the
intervention
(3 – 30
minute
consultations)
does not
necessarily
reduce the
number of
medications
taken.
Although not
a primary
outcome, days
hospitalized
was found to
be reduced in
the
intervention
group.
Yes, even
with the

POLYPHARMACY INTERVENTION

Article Title,
Author, etc.
(Current APA
Format)

Study
Purpose

Sample
(Characteristi
cs of the
Sample:
Demographics
, etc.)

73

Methods

Study Results

Level of
Evidence
(Use Melnyk
Framework)

Study
Limitations

Donyai, P.
(2017). Patient
views about
polypharmacy
medication
review clinics
run by clinical
pharmacists in
GP practices.

regarding a
patientcentered
clinical
pharmacistled
polypharmacy
medications
review service
incorporated
within GP
clinics.

75 years of age
or older with
15 or more
prescribed
medications,
served by one
of 34 GP
practices in
southeast
England.

questionnaire
was analyzed
using
thematic
analysis and
descriptive
statistics.

helpful by 83% design study
of respondents,
80% stated
they
understood
their
medications
better, and 94%
stating
medicationrelated
concerns
before the
review had
their concern
addressed.

eligible for a
medication
review
attended, and
of those
patients, only
40% filled out
a feedback
questionnaire.
Views of the
intervention
were not
measured for a
longer period
of time.

Urfer, M., Elzi,
L., Dell-Kuster,
S., & Bassetti,
S. (2016).
Intervention to
improve
appropriate

Assess the
safety and
efficacy of a
prescriber
checklist for
reducing
polypharmacy

A convenience
sample of 450
patients aged
65 or older,
consecutively
hospitalized in
the internal

Singlecenter,
intervention,
quasiexperimental,
before-after,
cohort study.

The
intervention
was associated
with a 22%
reduction in
PIMs
prescribed at

This study
does not have
the same
strength of
evidence as a
randomized
control study.

Level 4:
correlational
design cohort study

Would Use as
Evidence to
Support a
Change?
(Yes or No)
Provide
Rationale.
limitations of
patient
response,
patients saw
medication
reviews
positively.
Patient
understanding
of their
medications is
important step
in
deprescribing
and
decreasing
polypharmacy
Yes, an easy
to use
intervention
checklist
produced a
significant
reduction in

POLYPHARMACY INTERVENTION

Article Title,
Author, etc.
(Current APA
Format)

Study
Purpose

prescribing and
reduce
polypharmacy
in elderly
patients
admitted to an
internal
medicine unit.

and
inappropriate
prescribing
using the
STOPP
criteria as well
as the START
criteria to
identify
potentially
inappropriate
prescribing
omissions.

Van der
Linden, L.,
Decoutere, L.,

Assess the
effect of a
pharmacist

Sample
(Characteristi
cs of the
Sample:
Demographics
, etc.)
medicine
wards, of a
Swiss hospital.
Patients were
prescribed 5 or
more
medications at
admission.
The control
group will be
450
consecutively
admitted
patients in the
same wards,
with the same
characteristics,
during the
same time
period the
previous year.
A convenience
sample of 172
patients

74

Methods

A
monocentric,
perspective

Study Results

Level of
Evidence
(Use Melnyk
Framework)

discharge.
Although an
overall
decrease in the
number of
prescription
medications at
discharge
occurred, it
was less than
the 20%
hypothesized.
The expected
reduction in the
risk of
potentially
inappropriate
prescribed
omissions at
discharge did
not occur.
In the
Level 3:
intervention
quasigroup, more
experimental

Study
Limitations

Would Use as
Evidence to
Support a
Change?
(Yes or No)
Provide
Rationale.

The
generalizability
of the study is
questionable
with execution
at a single site.
Rotation of
Internal
Medicine
physicians to a
different ward
every 1-2
months can
skew results.

the risk of
PIMs at
discharge,
even with the
study
limitations.

There was no
attempt to
randomize the

Yes, the safe
reduction of
prescribed

POLYPHARMACY INTERVENTION

Article Title,
Author, etc.
(Current APA
Format)

Walgraeve, K.,
Milisen, K.,
Flamaing, J.,
Spriet, I., &
Tournoy, J.
(2017).
Combined use
of the
rationalization
of home
medication by
an adjusted
STOPP in older
patients
(RASP) list and
a pharmacistled medication
review in very
old inpatients:
Impact on
quality of
prescribing and
clinical
outcome.

Study
Purpose

intervention
using the
Rationalize
home
medication by
an Adjusted
STOPP in
older Patients
(RASP) on
inappropriate
prescribing,
polypharmacy
, and clinical
outcomes.

75

Sample
(Characteristi
cs of the
Sample:
Demographics
, etc.)

Methods

admitted to one
of three acute
geriatric wards
in a university
hospital in
Flanders,
Belgium.

control trial.
Assignment
to control or
intervention
arm
determined
by ward.

Study Results

Level of
Evidence
(Use Melnyk
Framework)

medications
design
were
discontinued
by discharge,
including
PIMs,
compared to
the control
group. In the
control group
there was
significant
improvement
in quality of
life, decrease in
emergency
department
(ED) visits and
hospitalizations
and no adverse
health events.

Study
Limitations

ward
assignment at
admission.
Follow-up of
patients was
limited to 3
month for ED
visits and
hospitalization.
The cause of
ED visits was
not tracked.
The university
hospital setting
may not be
generalizable
to other acute
care setting
hospitals.

Would Use as
Evidence to
Support a
Change?
(Yes or No)
Provide
Rationale.
medications
in geriatric
patients has a
positive effect
on the quality
of life and a
downward
trend in
emergency
department
visits.
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168 South Howell Street | Hillsdale, Michigan 49242
517-437-4451 | www. hillsdale hospital. com

November 26, 2019
Attention: Institutional Review Board
Liberty University
Lynchburg, VA
RE: Catherine Steiner’s Doctor of Nursing Practice Scholarly Project
To Who It May Concern,
Hillsdale Hospital Outpatient Clinics are committed to improving patient care and health
through the application of the most up to date, evidence-based, best practices. Ms.
Catherine Steiner’s Doctor of Nursing Practice Scholarly Project: The Impact of an
Evidence-based Protocol to Enhance Provider Awareness and Confidence in Addressing
Polypharmacy in the Outpatient Setting aligns with our commitment and we are please to
support this project pending Liberty University IRB approval.
The outpatient clinics that will be eligible to participate in the project are: Hillsdale
Health & Wellness Clinic, Hillsdale, MI; Litchfield Health Clinic, Litchfield, MI;
Reading Health Clinic, Reading, MI; and Three Meadows Medical, Hillsdale, MI.
Please feel free to contact me for further assistance.
Sincerely,

Seth Gibson
Seth Gibson, Administrator
Outpatient Clinics
Office: 517-439-2730
Email: sgibson @ Hillsdale hospital.com
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Hillsdale Medical Associates, PLC
1456 Cross Street | Hillsdale, MI 49242
Phone: 517-439-0200

December 3, 2019
Attention: Institutional Review Board
Liberty University
Lynchburg, VA
RE: Catherine Steiner’s Doctor of Nursing Practice Scholarly Project
To Who It May Concern,
Hillsdale Medical Associates, PLC is committed to improving patient care and health
through the application of the most up to date, evidence-based, best practices. Ms.
Catherine Steiner’s Doctor of Nursing Practice Scholarly Project: The Impact of an
Evidence-based Protocol to Enhance Provider Awareness and Confidence in Addressing
Polypharmacy in the Outpatient Setting aligns with the practice’s commitment and we are
please to support this project pending Liberty University IRB approval.
Please feel free to contact me for further assistance.
Sincerely,

Dan McCance, DO
Dan McCance, DO
Email: hmedicalassoc

@comcast.net
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CONSENT FORM
An Evidence-based Intervention to Enhance Provider Awareness and Confidence
in Addressing Polypharmacy
Catherine M. Steiner, NP
Liberty University
School of Nursing
You are invited to be in a research study on increasing prescribing clinician’s awareness and
confidence in addressing polypharmacy. You were selected as a possible participant because
you are a prescribing healthcare provider for patients in an outpatient clinic, either owned or
affiliated with Hillsdale Hospital, and you work an average of 20 hours or more weekly seeing
patients as their primary care provider. Please read this form and ask any questions you may
have before agreeing to be in the study.
Catherine M. Steiner, a doctoral candidate in the School of Nursing at Liberty University, is
conducting this study.
Background Information: The purpose of this study is to determine if an evidence-based tool
for deprescribing and appropriate prescribing can increase clinician awareness and confidence to
address polypharmacy.
Procedures: If you agree to be in this study, I would ask you to do the following things:
1. Complete confidential pre-survey form. This will take approximately 8 minutes
2. Take part in an introductory session providing instruction on the use of the deprescribing
tool. Tool will be distributed at the beginning of the session. This will take
approximately 10 minutes.
3. Complete confidential follow-up survey by email, 4 weeks after introductory session.
This will take approximately 8 minutes.
Risks: The risks involved in this study are minimal, which means they are equal to the risks you
would encounter in everyday life.
Benefits: The direct benefits participants may receive from taking part in this study are increased
awareness and confidence in addressing polypharmacy through deprescribing and appropriate
prescribing.
Compensation: Participants will not be compensated for participating in this study.
Confidentiality: The records of this study will be kept private. Any published report will not
include information that will make it possible to identify a subject. Research records will be
stored securely, and only the researcher will have access to the records. Data will be stored in a
password-protected file, on a password locked computer. Completed surveys will be stored in a
locked, fireproof, file cabinet located in the researcher’s private residence. Data may be used in
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future presentations, with the privacy of the participants maintained. After three years, all
electronic records will be deleted and original surveys will be shredded.
Voluntary Nature of the Study: Participation in this study is voluntary. Your decision whether
or not to participate will not affect your current or future relations with Liberty University or
Hillsdale Hospital. If you decide to participate, you are free to not answer any question or
withdraw at any time without affecting those relationships.
How to Withdraw from the Study: If you choose to withdraw from the study, please contact
the researcher at the email address/phone number included in the next paragraph. Should you
choose to withdraw, data collected from you, will be destroyed immediately and will not be
included in this study
Contacts and Questions: The researcher conducting this study is Catherine M. Steiner. You
may ask any questions you have now. If you have questions later, you are encouraged to
contact her at 517-290-8611 and/or csteiner4 @ liberty.edu. You may also contact the
researcher’s faculty chair, Dr. Ken Thompson, at kthompson55 @ liberty.edu.
If you have any questions or concerns regarding this study and would like to talk to someone
other than the researcher, you are encouraged to contact the Institutional Review Board, 1971
University Blvd., Green Hall Ste. 2845, Lynchburg, VA 24515 or email at irb@liberty.edu.
Please notify the researcher if you would like a copy of this information for your records.
Statement of Consent: I have read and understood the above information. I have asked
questions and have received answers. I consent to participate in the study.

_____________________________________________________________________________
Signature of Participant
Date
_____________________________________________________________________________
Signature of Investigator
Date
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